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AP-1   activator protein 1
Apo   apolipoprotein
CD   cluster of differentiation
CE   cholesteryl ester
CEase   cholesteryl esterase
CS   chondroitin sulfate
DS   dermatan sulfate
EC   endothelial cell
ECM   extracellular matrix
EDTA   ethylenediamine tetra-acetic acid
E-LDL   enzymatically modified LDL
ERK   extracellular signal-regulated kinase
FFA   free fatty acid
GAG   glycosaminoglycan
HDL   High density lipoprotein
H-LDL   hydrolase-modified LDL
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IL   interleukin
JNK   c-Jun N-terminal kinase
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LDL   low density lipoprotein
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ABSTRACT
ABSTRACT
Atherosclerosis is an inflammatory disease characterized by the appearance of small extracellular lipid droplets, formation of foam cells, and secretion of pro-inflammatory cytokines by vascular 
cells in the arterial intima. There is substantial evidence that the extracellular lipid droplets are derived 
directly from aggregated and fused low density lipoprotein (LDL) particles. However, native LDL 
particles do not aggregate or fuse unless they have been extensively modified. In fact, a variety of 
proteolytic, lipolytic, and oxidative enzymes and agents that are capable of degrading LDL in vitro, 
have also been found in the arterial wall. 
Human Type IIA secretory phospholipase A
2
 (PLA
2
) is an enzyme whose plasma level may increase 
dramatically during inflammatory diseases. It has been found in all the stages of atherosclerotic 
lesions, and has been shown to be able to degrade LDL in vitro. In addition, there is indirect 
evidence that once apolipoprotein B-100 containing lipoproteins enter the intima, hydrolysis of 
phosphatidylcholine, the major phospholipid of the LDL surface, by a PLA
2
-like activity takes 
place. In this study, Type IIA secretory PLA
2 
was shown to induce fusion of the LDL particles in 
the presence of proteoglycans (PGs), an important structural component of the arterial intima. In 
fact, the presence of PGs appeared to be a prerequisite for the lipolytic particle fusion. In addition, 
the binding strength of the fused LDL particles to PGs appeared to be increased, which promoted 
accumulation of the lipolyzed LDL to the PG-matrix. Enrichment of the PLA
2
-treated LDL with free 
fatty acids and lysophosphatidylcholines abolished fusion of the lipolyzed particles and detached 
a fraction of the PG-bound particles, suggesting that removal of the reaction product may have an 
important regulatory role in the formation of lipid droplets and their retention by PGs.
Extracellular discharge of the lysosomal enzymes has been shown to be a common physiologic 
response to a variety of inflammatory stimuli. Cathepsin D and lysosomal acid lipase are lysosomal 
hydrolases that play major roles in the degradation of LDL in lysosomal compartments. In this study, 
we could show that both enzymes exist extracellularly in the human atherosclerotic intima and that, 
upon activation, human monocyte-derived macrophages can secrete these enzymes into the cell 
culture media. Incubation of LDL with the macrophage-conditioned media containing cathepsin D 
and lysosomal acid lipase (among other secreted  hydrolases) induced fusion of LDL particles in 
vitro. Analysis of this hydrolase-modified LDL revealed that cathepsin D and lysosomal acid lipase 
had major roles in the degradation of LDL by macrophage-conditioned media. These particles 
were taken up avidly by macrophages and human coronary artery smooth muscle cells, which 
were transformed into foam cells. Hydrolase-modified LDL also induced expression and secretion 
of pro-inflammatory chemokines and cytokines, such as interleukin 8, monocyte chemoattractant 
protein 1, and interleukin 6. It was found that secretion of interleukin 8 from hydrolase-modified 
LDL-treated macrophages involved activation of p38 mitogen-activated protein kinase and nuclear 
translocation of nuclear-factor kappa B.
Taken together, our in vitro data are compatible with the idea that PLA
2
 and lysosomal acid hy-
drolases, which have both been found in human atherosclerotic lesions, are able to transform LDL 
into fused particles, which resemble extracellular lipid droplets found in the arterial intima during 
atherogenesis.
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Cardiovascular diseases, notably coronary artery disease and carotid artery disease, are the leading cause of death and illness in western countries. The pathogenesis of atherosclerosis, 
the disease process behind coronary and carotid artery disease, is characterized by accumula-
tion of lipids and fibrosis in the inner layer of the wall of these arteries. The first visible sign of 
atherosclerosis is the appearance of small lipid droplets in the subendothelial proteoglycan-rich 
layer of the arterial intima. There is substantial evidence that most of these early matrix-associated 
extracellular lipid droplets are derived directly from modified LDL. Aggregation, and especially 
fusion of enzymatically-modified LDL has been shown to increase retention of the modified LDL 
particles in human aortic proteoglycans in vitro. In addition, the proteoglycans and glycosaminogly-
cans have been shown to enhance the enzymatic modifications of both protein and lipid moieties 
of the LDL particle. However, only a few of the physiologically relevant enzymes are currently 
known to induce formation of fused LDL particles. 
In the early atherosclerotic lesions, the subendothelial lipid droplets disappear when monocytes 
migrate into the intima, differentiate into macrophages, and transform into foam cells, suggesting 
that the droplets are ingested by the macrophages. Indeed, aggregated and fused LDL particles 
have been shown to be taken up avidly by macrophages and smooth muscle cells, and to induce 
their transformation into foam cells in vitro. In addition, lipid-laden macrophages and smooth 
muscle cells have been shown to express various atherogenic agents, such as pro-inflammatory 
cytokines. Thus, aggregation and fusion of modified LDL particles may play a key role during 
atherogenesis.
The present series of investigations characterize novel types of non-oxidative modifications of 
LDL that induce fusion of the LDL particles and increase their atherogenic properties. 
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1. The low density lipoprotein (LDL)
1.1 Carriers of cholesterol
Cholesterol is a central molecule in atherosclerosis. Endogenously synthesized and chylomicron remnant-delivered dietary cholesterol is packed into very low density lipoproteins (VLDLs) 
in the liver and secreted into the blood plasma. The bulk of the cholesterol in VLDL particles 
exists as cholesteryl esters. VLDL is transformed into LDL by sequential lipolysis by the lipases, 
e.g. lipoprotein lipase, in the plasma. Once in tissues, LDL particles bind to LDL receptors on the 
cell surface, become endocytozed by the cells, and are degraded in the lysosomal compartments 
by acidic hydrolases [27]. Cholesterol diffuses out of the lysosomes and is consumed by the cells. 
The cholesterol homeostasis in the peripheral cells is maintained by regulation of the synthesis of 
LDL receptors, storage as cytoplasmic lipid inclusions, and active release of excess cholesterol 
through distinct cholesterol efflux pathways. The surplus cholesterol is captured from the cell 
membranes by high density lipoproteins (HDLs) or apolipoproteins and is then delivered to the 
liver for secretion.
1.2 Structure of LDL
LDL is a heterogeneous group of particles varying greatly in size, composition, and structure. Plasma 
LDL particles are distributed as a continuum over the density range of 1.019-1.063 g/ml and the 
diameter of the particles varies between 18 and 25 nm. LDL particles contain a hydrophobic core 
of nonpolar lipids composing of, on average, 1600 molecules of cholesteryl esters (CEs) and 170 
molecules of triglycerides and a amphipatic surface monolayer comprising about 700 molecules 
of phospholipids and a single copy of apolipoprotein B-100 (apoB-100) (Reviewed by Hevonoja 
et al. (2000)) [92] (Figure 1). Unesterified cholesterol (UC) molecules are partitioned in both the 
core and the surface of the particles, the former compartment containing, on average, 200 and the 
latter 400, molecules of UC. The main phospholipid components in the surface monolayer are 
phosphatidylcholines (PCs) (about 450 molecules/ particle) and sphingomyelins (SMs) (about 
185 molecules/particle). In addition, LDL particles carry lipophilic antioxidants, such as α- and 
γ-tocopherol, carotenoid, oxycarotenoid, and ubiquinol-10 molecules and enzymes, such as platelet 
activating factor-acetylhydrolase [281;284]. 
According to a new putative model, the structure of LDL can be divided into three layers: 
core, interfacial layer, and surface [92]. The interfacial layer consists of fatty acid chains of 
phospholipids and surface penetrating core molecules, and is likely to have a crucial role in the 
molecular properties of LDL. The lipid constituents of the interfacial and surface layers of LDL 
are not homogenously distributed. It has been shown that PC associate more closely with apoB-
100 than SM and UC interacts more closely with all the physiologically relevant SM species in 
membranes [217]. However, at least the interaction of SM with UC is suggested to be due to the 
hydrophobic mismatch between the lipid constituents rather than to specific interactions [97]. 
Thus, these different environments of the LDL surface and the interfacial layer, i.e. the apoB-100 
12
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Figure 1. Schematic molecular model of an LDL particle.  Reproduced from Hevonoja et al. (2000) with permission of the 
Publisher. Abbreviations: ApoB-100; apolipoprotein B-100, CE; cholesteryl ester, PC; phosphatidylcholine, SM; sphingomyelin, 
TG; triglyceride, UC; unesterified cholesterol.
containing environment, PC rich and UC poor areas, and SM rich and UC rich areas may have important 
physiological roles. 
The protein component of LDL, apoB-100, is one of the largest known monomeric proteins. It consists of 
4536 amino acid residues and has a calculated molecular weight of about 513 000 [47;53;125;138;306]. It 
is located at the surface of LDL as a “ribbon and bow” conformation [46] and has a pentapartite structure 
consisting of both amphipathic α-helical domains and β-stranded domains [243;244]. A delipidated 
apoB-100 has been shown to contain eight potential heparin-binding sites, and two potent proteoglycan 
(PG)-binding segments have been suggested to reside in residues 3147-3157, site A, and 3359-3367, 
site B [194]. In addition, site B, the most potent PG-binding site, has been shown to contain a binding 
site for the LDL receptor [24]. 
SM PC TG CE
ApoB-100:
α-HELIX
ApoB-100:
β-SHEETUC
~2 nm
LysoPC
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2. Arterial wall
2.1. Arterial layers 
The arterial wall consists of three histologically distinct layers: the intima, the media, and the adventitia (Figure 2). The lumen of the artery and the intima are separated by a mon-
olayer of endothelial cells (ECs). ECs, at the blood-tissue interface, play an essential role in 
homeostasis of the circulation and the vessels by secreting agents that regulate relaxation and 
constriction of the arteries. In addition, upon various stimuli, they can express adhesion mol-
ecules and cytokines that can have critical roles in atherogenesis. ECs are seated on the base-
ment membrane which mainly consists of type IV collagen, laminin, and heparan sulfate (HS) 
PGs. HSPGs play an important role in the assembly and structure of the basement membrane 
but also provide a physical barrier to cells and lipoproteins. In fact, a decrease in the amount 
of subendothelial HS [95] could be one factor that increases the influx of LDL into the intima 
during atherogenesis. The intima consists of two layers that are hardly distinguishable by light 
microscopy in segments of normal arteries. The inner layer of the intima, the PG rich layer, 
consists of PGs, which are the most voluminous of the components of intimal extracellular 
matrix (ECM). In addition to PGs, the layer contains different types of collagens, hyaluronan, 
and glycoproteins such as fibronectin and laminin. There are also few isolated smooth muscle 
Figure 2. Schematic  illustration of arterial layers. Abbreviations: col; collagen, e; elastin, EC; endothelial cell, 
EEL; external elastic lamina, FB; fibroblast, IEL; internal elastic lamina, lv; lymphatic vessel, MC; mast cell, MF; 
macrophage, nf; nerve fiber, PG; proteoglycan, SMC; smooth muscle cell, vv; vasa vasorum.
14
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cells (SMCs) of synthesizing phenotype, macrophages, and mast cells in the intima. The outer 
layer of the intima, the musculoelastic layer, contains SMCs of contractile phenotype, collagen, 
and elastin fibers. 
The middle layer of the arterial wall, the media, which is separated from the intima by an internal 
elastic lamina, consists of diagonally oriented SMCs, collagens, small elastic fibers, and PGs. 
Medial SMCs are of contractile phenotype and are bound on each side by fenestrated sheets of 
elastic tissue, which provide the artery with tensile strength and determine the state of constriction 
of the artery. 
The outermost layer of the arterial wall, the adventitia, is separated from the media by the external 
elastic lamina. It consists primarily of fibroblasts, smooth muscle cells, and mast cells surrounded 
by bundles of collagens and PGs. The layer contains nerve fibers, which enter the media and 
participate in the regulation of arterial tone. The layer also contains small blood vessels (vasa 
vasorum), which supply blood to the outer 2/3 of the media and the lymphatic vessels which 
originate in the media.
Versican Biglycan Decorin
Core protein
Glycosaminoglycan chain
Figure 3. Structure of the major chondroitin and dermatan sulfate proteoglycans in the arterial wall.
2.2. Intimal proteoglycans (PGs)
PGs are characterized by the presence of one or more long, unbranched polyanionic glycosaminogly-
can (GAG) chains that are covalently attached through O-glycosidic linkage to serine residues in 
the core glycoprotein (Figure 3). The most prominent GAG in the intima is chondroitin sulfate 
(CS), dermatan sulfate, HS, and keratan sulfate also being present. CSPG is present throughout the 
interstitial space of normal ECM whereas HS PGs appear in arterial basement membranes and are 
associated with cellular membranes [17;296]. The major CSPGs in the mammalian arterial wall 
are the large versican and the small leucinerich PGs, decorin and biglycan (Reviewed by Williams 
(2001)) [298]. In the interstitium, versican interacts with hyaluronan [139], and fills the interstitial 
space of the vascular ECM not occupied by cells or the fibrous components [74]. The principal 
source of PGs in the arterial intima are SMCs, but also ECs [296], differentiated macrophages [64], 
14
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Type I
Type II
A. B. 
Type III
Type IV
Type V
Type VI Type VII Type VIII
Foam cell
Extracellular
lipid
Extracellular 
matrix
Smooth muscle
 cells
(Type V + 
surface defects)
(Type V +
calcification)
(Lipid poor 
Type V lesion)
Figure 4. Classification of atherosclerotic lesions. Adapted from Stary (2000). Type II lesions can be either 
highly (A) or moderately (B) susceptible for development of more advanced lesions.
lymphocytes [128] and mast cells [129] secrete small amounts of PGs upon activation. 
3. Changes in the arterial intima during atherogenesis 
3.1. Classification of the stages of atherosclerosis
According to the American Heart Association, atherosclerotic lesions were divided into six types based on their histological composition and structure [261;262]. In the latest commentary, 
Stary (2000) clarified the classification by adding two new lesion types to the list [260]. Type I 
lesion is characterized by the presence of macrophage foam cells in the subendothelial layer of the 
16
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intima (Figure 4). Accumulation of macrophage-derived foam cells and macrophages in addition 
to some SMC-derived foam cells as layers in the intima is classified as Type II atherosclerotic 
lesion. Type II lesions can be subdivided into IIa and IIb according to their susceptibility to the 
development of more advanced lesions, i.e. Type IIa being highly susceptible and Type IIb mod-
erately susceptible [260]. This type of lesion can be seen with the naked eye as a “fatty streak”. 
These early lesions can be found in arteries of most children around puberty [260], but since they 
do not obstruct the arterial lumen or disrupt the structure of the intima, they are clinically silent. 
Type III (intermediate) lesions are characterized by adaptive intimal thickening and the appearance 
of small pools of extracellular lipid in the musculoelastic layer of the intima, that do not form a 
confluent lipid core. When small extracellular lipid pools form a confluent lipid core, the lesion is 
classified as a Type IV lesion. The intima above the core appears similar to that in Types II and III. 
The adaptive development of a fibromuscular cap above the core is characteristic of the Type V 
lesions. If these fibrotic lesions contain surface defects, hematoma, or thrombosis, they are called 
Type VI lesions. Calcified Type V lesions are called Type VII and and lipidpoor type V lesions 
are called Type VIII lesions. However, progression of the lesions can vary, i.e. Type IV lesion can 
proceed directly to Type VI, VII, or VIII [260]. 
          
Proteoglycan Type    Localization   
    Normal intima  atherosclerotic intima 
Versican CSPG  +++   ++++
Biglycan CS/DSPG +   ++++
Decorin  CS/DSPG +/-   ++
Perlecan HSPG  ++   +   
Table I. The most prominent proteoglycans of human arterial intima. Adapted from Reviews by Wight (1995) [297], 
Pillarisetti (2000) [206], Williams (2001) [298], and Khalil (2004) [118]. Abbreviations: CSPG; chondroitin sulfate pro-
teoglycan, DSPG; dermatan sulfate proteoglycan, HSPG; heparan sulfate proteoglycan.
3.2. PGs in atherosclerotic lesions
Retention of lipoproteins occurs primarily in the areas that are known to be prone to develop le-
sions, i.e. in the bifurcation sites of the arteries with eccentric thickening of the intima. These areas 
contain large amounts of ECM, mostly PGs that have been expressed by SMCs due to the abnormal 
shear stress. In fact, upon mechanical strain, cultured SMCs have been shown to secrete PGs with 
increased size and sulfation [142]. In addition to mechanical stress, also oxidized LDL (oxLDL), 
hypoxia, an elevated concentration of free fatty acids (FFAs), and complement activation have been 
shown to increase the length of GAG chains and the chondroitin-6-sulfate/chondroitin-4-sulfate 
ratio of the PGs in vitro (Reviewed by Chait & Wight (2000)) [38]. Also, proliferation of SMCs 
increases the secretion of PGs that have longer GAG chains and increased affinity for LDL [29]. 
Indeed, retained lipoproteins in early atherosclerotic lesions have been shown to be associated 
with PGs, especially CSPGs. In a recent immunohistochemical study it was demonstrated that 
versican was the most prominent PG in non-atherosclerotic regions of the coronary artery [191] 
(Table I). In atherosclerotic lesions, both versican and the small, leucine-rich dermatan sulfate 
PG, biglycan, were enriched [191]. Versican colocalized regionally with the formation of foam 
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cells in the subendothelial area of the intima, was the predominant PG in vascular injury, and was 
localized close to the lipid-filled regions, whereas biglycan directly colocalized with apoB and 
apoE in advanced plaque.  Biglycan has also been shown to be prominent in ECM immediately 
adjacent to areas of macrophage infiltration [191] and to be synthesized by arterial SMCs [112]. 
Increased GAG chain length of biglycan has been found in PG extracts from atherosclerosis-
susceptible arteries [242] suggesting that biglycan may bind extracellular lipid droplets in the 
atherosclerotic lesions. In addition, decorin, that has not been found in the healthy intima, was 
enriched in extracellular regions of the fibrous cap [216]. Taken together, chondroitin-sulfate rich 
PGs partially colocalize in atherosclerotic lesions, but they participate unequally in lipoprotein 
retention and exert unequal regulatory effects that are related to atherogenesis. Thus, the precise 
role of PGs during atherogenesis remains to be clarified. 
3.3. Accumulation of extracellular lipid
There is substantial evidence that initiation of atherosclerosis is characterized by the appearance 
of extracellular lipid droplets. Thus, Tirziu et al. [282] showed that even the grossly normal human 
arterial intima may contain extracellular small lipid droplets and vesicles. In addition, in animal 
studies, infusion of human LDL into New Zealand White rabbits has been shown to induce the 
rapid appearance of both aggregated LDL-sized particles and enlarged lipid droplets within ECM 
[190]. Lipid droplets have been shown to be located subendothelially in human carotid arteries 
and their disappearance coincided with the formation of foam cells [200]. Moreover, in several 
other animal studies, the appearance of extracellular lipid droplets and vesicles has been shown to 
precede migration of monocytes into the vascular wall [4;70;73;82;169;178;189;248;275]. Taken 
together, the above results suggest that the appearance of aggregated and fused LDL-derived par-
ticles extracellularly in the arterial intima could be an initiative factor during atherogenesis. 
 
The lipid particles that have been extracted from the arterial intima can be divided into four cat-
egories: LDL-like particles, small lipid droplets, lipid vesicles, and VLDL/intermediate density 
lipoprotein-like particles (Reviewed by Öörni et al. (2000)) [320]. Arterial LDL-like particles are 
spherical particles slightly larger than LDL and they have marks of fragmentation of apoB-100, 
have a slightly lower hydrodynamic density, contain a normal or slightly increased proportion of 
SM and lysophosphatidylcholine (LPC) but a smaller amount of PC, contain markers of oxida-
tion, and have increased electrophoretic mobility. Arterial small lipid droplets are enriched in 
esterified cholesterol, have decreased amounts of phospholipids and protein, have a low hydrated 
density, and the sizes of the droplets are in the range of 40-200 nm. Lipid vesicles do not show 
immunoreactivity against apoB-100 antibodies, are rich in SM and UC, and contain albumin in 
their core suggesting that they have been formed extracellularly. Finally, the VLDL/intermediate 
density lipoprotein-like particles resemble plasma VLDL that contain apoE [218;312], are poor 
in triglycerides [218;312], and their apoB-100 is almost intact [218].
18
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4. Aggregation and fusion of LDL
4.1. Lipolytic modification of LDL
4.1.1. Modification of LDL by phospholipase A2 (PLA2)
The surface monolayer of LDL consists of phospholipids, UC, and apoB-100 (see Figure 1). There is indirect in vivo evidence that once apoB-100 containing lipoproteins enter the intima, 
hydrolysis of PC, the major phospholipid of the LDL surface, by PLA
2
-like activity takes place. 
Thus, LDL extracted from vascular tissue appeared to have a decreased content of PC [58;271], a 
lower content of linoleic acid than plasma LDLs [31], and a higher proportion of LPC in the phos-
pholipid fraction [315]. In addition, the concentration of Type IIA secretory PLA
2
 (sPLA
2
) in plasma 
has been shown to be a strong independent risk factor for coronary heart disease [135;211]. 
PLA
2
s are a group of enzymes that catalyze the hydrolysis of the sn-2 fatty acyl ester bond in PC 
of LDL, yielding a FFA and a lysophospholipid [1]. Both cellular and secreted types of PLA
2
s are 
known (Table II). The expanding family of mammalian sPLA
2
s now comprises 10 types of iso-
forms: IB, IIA, IIC, IID, IIE, IIF, III, V, X, and XII [75;134;250]. All the sPLA
2
s have a conserved 
overall three-dimensional structure and a Ca2+dependent catalytic mechanism. Lipolysis of LDL 
by sPLA
2
s in vitro has been shown to reduce the size of the LDL particles [1;122;235;303;319] 
(Figure 5), and to change the molecular packaging of the surface lipids and apoB-100 [122] which 
There is substantial biochemical evidence that the extracellular lipid in the arterial intima is derived 
directly from plasma LDL. First, the fatty acyl pattern of CEs of the extracellular lipid droplets 
resembles that of plasma lipoproteins rather than that of the cytoplasmic CE droplets of foam cells 
[83;253]. Second, the diameter of most extracellular lipid droplets (range 30–400 nm) is smaller 
than that of intracellular lipid droplets (range 400–6000 nm) [42;84]. Third, similar droplets can 
be formed by enzymatic modifications of LDL in vitro. It has been shown that proteolysis of LDL 
by neutral proteases of mast cell granules [126;197], by α-chymotrypsin [198;201;205], by trypsin 
and pronase [205], lipolysis by PLC [267], by SMase [305;319], by PLA
2 
[303;319], oxidation 
of LDL [40], and the combined action of a protease and a lipase [18;86;286] produce aggregated 
and/or fused LDL that resemble extracellular lipid droplets in the atherosclerotic intima.
Interestingly, the lipid composition in the necrotic lipid core of atherosclerotic lesions seems to 
depend on the macrophages and macrophage-derived foam cells. Thus, beneath the macrophage-
foam cells of the small initial fibrolipid lesions, the extracellular lipid consists mostly of small 
vesicles enriched in UC and cholesterol crystals, whereas in the absence of foam cells, the lipid 
appears as small lipid droplets enriched with CE (Reviewed by Öörni et al. (2000) [320]). In addi-
tion, Ball et al. (1995) have shown that lipid cores in early lesions contain markers of macrophages, 
i.e. ceroid and CD68 antigen [13], demonstrating that the dying macrophages may be, at least, a 
partial source of the core lipids. Therefore, the relative contributions of extracellular modification 
of liproproteins and apoptosis/necrosis of foam cells in the formation of the lipid core remain to 
be clarified.
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Table II. Mammalian PLA2 enzymes. Adapted from Reviews by Six and Dennis (2000)
a [250] and Kudo and Murakami 
(2002)b [134]. Abbreviations: c; cytoplasmic, i; Ca2+-independent, PAF-AH; platelet-activating factor acetylhydrolase, 
s; secretory.
Figure 5. Schematic illustration of structural changes in PLA2-treated LDL particle. PLA2 induces decrease in the 
diameter of LDL particle. Reproduced from Hevonoja et al. (2000) with permission of the Publisher. Abbreviations: ApoB-
100; apolipoprotein B-100, CE; cholesteryl ester, FFA; free fatty acid, PC; phosphatidylcholine, PLA2; phospholipase A2, 
SM; sphingomyelin, TG; triglyceride, UC; unesterified cholesterol.
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may lead to more rigid particles. In some of the studies, Type III sPLA
2 
[319] and Type V sPLA
2 
[303] have been shown to decrease the diameter of the individual LDL particles and to induce 
aggregation of a fraction of the particles [319]. The probable reason for the controversy between 
the aggregability of the PLA
2
-treated particles in different studies are differences in the experi-
mental design. Thus, in some studies, low concentration or absence of albumin prevented release 
of negatively charged FFAs and LPC from the PLA
2
-treated LDL particles [1;87;122], which may 
have inhibited the formation of aggregates of LDL particles. 
Types IIA, V, and X sPLA
2
s have been found in the atherosclerotic lesions [87;224;303]. How-
ever, there is a substantial difference in the specificity and inductivity of human sPLA
2
s. Whereas 
Type IIA sPLA
2
 hydrolyzes prefentially anionic phospholipids such as phosphatidylserine and 
phosphatidylglycerol, Type V sPLA
2
 [77;303] and Type X sPLA
2
 [87] efficiently degrade also PC. 
Enzymatic activity of Type IIA sPLA
2
 on LDL has been shown to be enhanced by GAGs and PGs 
[234;236;237], which increases the likelyhood that LDL becomes modified by Type IIA sPLA
2 
in the PGrich arterial intima. In contrast to Type IIA sPLA
2
, which was induced by minimally 
modified LDL [6] and lipopolysaccharide [102], Type V sPLA
2
 has been shown to be expressed 
either constitutively in differentiating monocytes in vitro [6] or by hyperlipidemia in C57BL/6 mice 
[102]. Thus, there is substantial evidence that secreted PLA
2
s exist in the human atherosclerotic 
lesions and the different types of PLA
2
s
 
can modify LDL in vivo, but the precise physiological 
functions of the individual sPLA
2
s are currently obscure.
4.1.2. Modification of LDL by phospholipase C (PLC) and sphingomyelinase  
          (SMase)
The other lipases that degrade phospholipids and have been shown to induce aggregation and/or 
fusion of LDL are PLC and SMase. PLC is an enzyme that hydrolyses PC and yields diacylglyc-
erol and phosphocholine. Hydrophilic phosphocholine is released from the LDL particle whereas 
diacylglycerol remains in the LDL particles [290] (Figure 6). PLC has been shown to increase 
the turbidity of LDL suspensions [267] and to induce  aggregation and/or fusion of the LDL 
particles in vitro [152; 210]. Moreover, PLC-treated LDL was avidly taken up and degraded by 
macrophages through an LDL receptor dependent pathway [267]. However, LDL isolated from 
the atherosclerotic intima does not contain detectable amounts of diacylglycerol nor has PLC been 
found extracellularly in the arterial intima. 
SMase is an enzyme that hydrolyses SM, another major phospholipid in the surface of LDL, 
yielding a water-soluble phosphocholine molecule, which is released, and a ceramide molecule, 
which is retained in the particle. At least four different SMases have been found in mammals: 
cation-independent lysosomal-type SMase [256], cytoplasmic cation-independent SMase [192], 
membrane-associated Mg2+-dependent SMase [45], and secreted Zn2+-dependent SMase [240;257]. 
In addition, apoB-100 of LDL has been suggested to have an intrinsic SMase activity [96]. Of the 
resident cell types in the human arterial intima, at least macrophages [240] and ECs [167] have 
been shown to secrete Zn2+-dependent SMase. In fact, there is evidence that at least a portion of 
the arterial SMase activity is cation-dependent, suggesting that membrane bound Mg2+-depend-
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Figure 6. Schematic illustration of structural changes in PLC- and SMase-treated LDL particles. PLC and SMase 
induce formation of hydrophobic micro domains. Reproduced from Hevonoja et al. (2000) with permission of the Pub-
lisher. Abbreviations: ApoB-100; apolipoprotein B-100, CE; cholesteryl ester, CER; ceramide, DAG; diacylglycerol, PC; 
phosphatidylcholine, SM; sphingomyelin, TG; triglyceride, UC; unesterified cholesterol.
ent and/or secreted Zn2+-dependent (sSMase) enzymes  may be active in the arterial wall [241]. 
Moreover, the amount of Zn2+ in atherosclerotic lesions [173] and in inflammatory regions [176] 
have been shown to be elevated, possibly permitting sSMase activity.
It has been shown that sSMase induces both aggregation and fusion of LDL particles in vitro 
[197;305;319]. The mechanism(s) for aggregation and fusion of SMase-treated LDL particles is 
suggested to include interactions between non-polar ceramide-enriched microdomains of attached 
particles [319] (Figure 6), membrane disruptive or fusogenic properties of ceramide [251;289], 
or hydrogen bonding between ceramide and the surface phospholipids of neighboring particles 
[305], but without involvement of apoB-100 [241]. It has been shown that arterial lipid droplets are 
mostly enriched with SM [239]. However, aggregated LDL droplets extracted from atherosclerotic 
lesions are enriched in ceramide [241] suggesting that aggregated LDL particles could have been 
produced at least partly by sSMase-like activity. 
4.2. Proteolytic modification of LDL  
ApoB-100 is an important structural component of the LDL surface and even its partial loss is likely 
to loosen the lipid packing on the surface (Figure 7). There is a number of different proteases that 
are capable of degrading apoB-100 of LDL in vitro, e.g. plasmin, kallikrein, thrombin, trypsin,  
α-chymotrypsin, chymase, and pronase, but only some of them, i.e. trypsin, α-chymotrypsin, 
chymase, and pronase, have been shown to induce aggregation and/or fusion of LDL particles. 
Thus, particle fusion was originally observed on the surface of isolated mast cells granule remnants 
[126]. In the remnants, chymase and carboxypeptidase A degraded apoB-100 of the remnant-bound 
LDL + PLC LDL + SMaseNative LDL
SMPCCEUCApoB-100 TG
Head Group +
DAG
Head Group +
CER
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Cathepsins are proteases that normally act in lysosomes, but can be actively secreted in various 
pathological conditions. Cathepsin D, the major cathepsin in lysosomes, in addition to cathepsins B, 
L, S, K, Y, and F, have been found to be expressed in atherosclerotic lesions [44;111;268;307;322]. 
In vitro, cathepsins B, L, and S [220], and cathepsins D and K [213;268] have been shown to 
be secreted by cultured vascular cells.  However, at present, cathepsin F is the only cathepsin 
that has been shown to induce aggregation and fusion of LDL [322]. The authors also showed 
that cathepsin F was expressed by a fraction of the intimal SMCs and ECs, but mostly localized 
the macrophage-rich areas of human coronary artery atherosclerotic plaques [322]. In addition, 
phenotypic differentiation of monocytes into macrophages induced expression and secretion of 
cathepsin F into the cell culture medium, suggesting that the enzyme could be secreted constitu-
tively by arterial macrophages. 
Loosening of the surface of LDL by proteolysis can also promote hydrolysis of the core lipids 
of LDL. Thus, a combined action of a protease that cannot alone induce fusion of the particles, 
such as plasmin [205], and cholesteryl esterase, can induce the formation of LDL-derived lipid 
droplets in vitro [286]. In addition, similar droplets can be produced by replacing plasmin with 
either trypsin, cathepsin H, or matrix metalloproteinases 2 and 9 [286], suggesting that the spe-
cificity of the protease does not play a significant role in rendering the core CEs accessible to 
cholesteryl esterases. These enzymatically modified particles, E-LDL, resemble chemically and 
morphologically the lipid droplets extracted from atherosclerotic lesions [18;41;73;130;245;248]. 
Indeed, by immunohistochemistry, similar E-LDL-like droplets have been found extracellularly 
Figure 7. Schematic illustration of structural changes 
in α-chymotrypsin-treated LDL particles. Proteolysis 
of apoB-100 with α-chymotrypsin loosens the surface of 
LDL and promotes fusion of LDL particles. Reproduced 
from Hevonoja et al. (2000) with permission of the Pub-
lisher. Abbreviations: ApoB-100; apolipoprotein B-100, 
CE; cholesteryl ester, PC; phosphatidylcholine, SM; sphin-
gomyelin, TG; triglyceride, UC; unesterified cholesterol.
LDL [127] and induced fusion of the GAG-bound 
LDL particles [126]. Later, chymase and tryp-
tase, two neutral proteases of human mast cells, 
have been shown to be expressed by mast cells 
in human aortic and coronary lesions [113;114] 
and the purified rat mast cell chymase has been 
shown to induce fusion of LDL even without 
GAGs [197]. Trypsin [205] and α-chymotrypsin 
[201;205], two proteases with specificity similar 
to chymase, have also been shown to induce fu-
sion of LDL particles. However, mere proteolytic 
fragmentation of apoB-100, as induced by plas-
min, kallikrein, and thrombin does not induce 
fusion of LDL particles [205]. Piha et al. (1995) 
showed that the release of peptide fragments from 
proteolyzed LDL was needed for fusion of the 
particles to occur [205]. Thus, only some of the 
proteases that can be found extracellularly in the 
human arterial intima, are able to degrade apoB-
100 of LDL and to induce fusion of LDL. 
LDL +α-chymotrypsinNative LDL
SM PC CE UC ApoB-100TG
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Figure 8. Schematic illustration of structural changes 
in an oxidized LDL particle. Oxidation leads to frag-
mentation and derivation of protein and lipid compo-
nents of LDL particle. Reproduced from Hevonoja et al. 
(2000) with permission of the Publisher. Abbreviations: 
ApoB-100; apolipoprotein B-100, CE; cholesterylester, 
MDA; malondialdehyde, PC; phosphatidylcholine, SM; 
sphingomyelin, TG; triglyceride, UC; unesterified cho-
lesterol.
in the insudative layer below macrophage foam cells and in the deeper part of the intima adjacent 
to the media in early human atherosclerotic lesions [285]. 
 
4.3. Oxidative modification of LDL 
There is considerable evidence that oxidative modification of LDL is directly related to the devel-
opment of atherosclerosis. Thus, oxidized forms of LDL have been isolated from atherosclerotic 
lesions, autoantibodies towards oxLDL have been found in patients [143] and in atherosclerotic 
animal models, and attenuation of atherosclerosis in experimental animals by oxLDL-antibodies 
has been presented (Reviewed by Steinberg (1997)) [263]. It has been suggested that atherosclerotic 
plaques contain transition metals [137], cyclooxygenase II which produces free radicals potentially 
capable of oxidizing LDL, 15-lipoxygenase,  and myeloperoxidase that could induce oxidation 
of arterial lipoproteins (Reviewed by Ylä-Herttuala (1998)) [311]. In addition, antioxidants have 
been shown to inhibit atherogenesis in animal studies [55;301], but human clinical trials have 
given some confusing results [263;311]. 
Of the various pro-oxidative agents, e.g. Cu2+ [94;201], 2,2’-azobis(2-amino-propane)hydrochloride 
[117], peroxynitrite [208], nitrogen dioxide gas [120], nitrite [39], hypochlorite [40;89], and the 
combined action of soybean lipoxygenase and PLA
2 
[40], at least Cu2+ [94;201], 2,2’-azobis(2-
amino-propane)hydrochloride [117], hypochlorite [40;89], and soybean lipoxygenase [40] have 
been shown to induce aggregation and/or fusion of LDL particles in vitro.  In contrast to most of 
the other modifications of LDL, oxidation can 
modify both the protein and the lipid components 
of LDL (Figure 8). Oxidation initially attacks the 
unsaturated fatty acids of the surface phospholip-
ids, which can then be hydrolyzed by endogenous 
PLA
2
 of the LDL particles. Release of the reac-
tion products, FFA and LPC, can increase the 
tendency of the particles to aggregate. Moreover, 
reactive aldehydes produced by peroxidation of 
the LDL lipids and/or direct degradation of apoB-
100 by oxidative agents can induce aggregation 
and fusion of LDL particles (Reviewed by Öörni 
et al. (2000)) [320]. In addition, extensive oxida-
tion decreases the mobility of the surface phos-
pholipids, disturbs lipid-protein interactions, and 
increases the polarity of the lipid phase [199]. 
Indeed, hydrophobic regions of apoB-100 of LDL 
have been shown to be preferentially degraded 
during oxidation [249], which may lead to their 
relocation to the surface of LDL with ensuing 
aggregation and fusion of the particles. 
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5. Atherogenic properties of aggregated and/or fused    
    LDL
5.1. Extracellular retention of LDL
Elevated levels of LDL increase atherosclerosis but the actual mechanism(s) are, however, poorly understood. Of the three competing hypotheses, the response-to-injury hypothesis 
[187;226;227], the oxidation hypothesis [208;264;265], and the response-to-retention hypothesis 
[299;300], the last one was gradually emerged as a central paradigm of the pathogenesis of athero-
sclerosis. This hypothesis holds that the atherogenicity of apoBcontaining lipoproteins depends on 
their increased plasma concentrations, increased retention of the particles in the intima, decreased 
efflux of the lipoprotein particles from the intima, and modification of the retained particles. As 
discussed above, the early extracellular lipids appear as small lipid droplets and vesicles sub-
endothelially in the ECM in humans and in experimental animals. Moreover, intimal apoB-100 
containing lipid droplets have been shown to associate closely with PGs and collagen fibrils in 
early atherosclerotic lesions [73;190;275]. 
Native LDL shows very low affinity to PGs at neutral pH and at the physiological ionic strength 
and calcium concentration in vitro, but the affinity has been shown to be increased substantially 
by aggregation and fusion of the particles. The binding of LDL to PGs is mediated by positively 
charged lysine and arginine residues of apoB-100 and negatively charged carboxyl and sulfate 
groups of GAG chains of PGs [28;108]. ApoB-100 contains eight different positively charged 
heparin-binding sequences that are partially buried in native LDL. Two of these sites (site A at 
residues 3148 to 3158 and site B at residues 3359 to 3369) have been proposed to act cooperatively 
in association with PGs. It has been shown that positively charged arginine and lysine residues in 
site B are critical for binding of LDL to CS/dermatan sulfate PGs and that mice expressing a defect 
in site B had reduced early atherosclerotic lesions in genetically engineered mice [252] suggesting 
that site B is the primary PG-binding site in apoB-100 of LDL. 
4.4. Other types of modification of LDL
The most simple, and also the most unphysiological, type of modification that produces aggregated 
and fused LDL is vortexing. Vortexed LDL is easy to make and it appears as different kinds of 
LDL droplets and vesicular structures [201]. Therefore, vortexed LDL can serve as a good tool 
for studying the atherogenic properties of aggregated and fused LDL.
In addition, two types of modified LDL, i.e. electronegative LDL [12] and naturally occuring 
multiply modified LDL [278], have been found in human plasma. They are both characterized by 
a decreased content of phospholipids, an increased content of UC, a higher negative charge of the 
particles, but increased tendency to aggregate [12;278], which may lead to their increased uptake 
by macrophages [279]. In addition, both types of modified LDL are depleted in sialic acids sug-
gesting that the particles are similar, if not even identical [277;280]. 
24
REVIEW OF THE LITERATURE
25
REVIEW OF THE LITERATURE
The conformation of apoB-100 on the surface of an LDL particle is dependent on the composition 
of the core lipids, the surface phospholipid content, and the diameter of the LDL particle. Thus, 
changes in the morphology of LDL can induce changes in the exposure of the PG-binding sites in 
apoB-100. For example, modification of LDL with PLA
2
 has been shown to alter the expression 
of apoB-100 epitopes on the LDL particle [122] and to increase the affinity of LDL to GAGs [235] 
and human aortic PGs [319]. Recently, Flood et al. [71] showed that in Type IIA sPLA
2
-modified 
LDL, site A acts cooperatively with site B to increase the affinity of LDL particles for arterial 
PGs, whereas enrichment of the LDL particle with cholesterol increased the affinity of LDL for 
PGs through a conformational change of site B. The authors speculated that the conformational 
changes of apoB-100 in Type IIA sPLA
2
-modified LDL were caused by defects in the phospholi-
pid composition of the LDL particle and by formation of smaller LDL, that has previously been 
shown to have an increased affinity for PGs [101]. In contrast, Öörni et al. [319] have shown that 
mere lipolysis of LDL by SMase or PLA
2
 did not affect the binding of the particles to PGs. In fact, 
in accordance with previous results [1;122;235;303], the mean diameter of all the PLA
2
-treated 
LDL particles was decreased, but the binding strength of the small particles appeared to be slightly 
lower than that of untreated LDL [319]. Instead, aggregation of the lipolyzed particles increased 
their binding strength for human aortic PGs. Moreover, fusion of the LDL particles induced by 
SMase increased the binding strength of the particles to PGs even more [319]. Similarly, fusion 
of LDL by proteolytic enzymes, such as mast cell granule proteases [197], α-chymotrypsin [198], 
and cathepsin F [322] has been shown to increase the binding strength of LDL particles to GAGs 
and PGs. In addition, aggregation and fusion of cathepsin F-treated LDL increased the ability of 
lipoproteins to bind to the PGs and led to accumulation of modified LDL in the PG matrix [322]. 
Analysis of the amount of active lysines, the lysine residues that are suggested to be involved in 
the binding of LDL to PGs, has revealed that fusion of LDL increases both the amount of active 
lysines per modified particle and the binding strength of the particles to PGs [198;319]. Taken 
together, aggregation and fusion of LDL increase the binding strength and retention of the par-
ticles to PGs. In addition, the likely reason for the observed increase in the binding strength of 
aggregated and fused LDL to PGs is a presence of many apoB-100 molecules in LDL aggregates, 
and in fused particles, reorganization of the apoB-100 with exposure of new basic areas at the 
surface of the enlarged particle. 
5.2. Intracellular accumulation of LDL
5.2.1. LDL receptor-mediated uptake of LDL
Native LDL is taken up mainly by the LDL receptor pathway, which is strictly controlled by the in 
flowing cholesterol and therefore does not generally lead to intracellular accumulation of cholesterol 
[27]. However, it has recently been shown that uptake of native LDL by activated monocyte-derived 
macrophages is increased, and that such macrophages are converted into foam cells [131;132]. 
Most probably at least a transient interaction of native LDL with PGs is needed in vivo for uptake 
of LDL by vascular cells and their subsequent transformation into foam cells. Indeed, uptake of 
versican-treated native-sized LDL particles has been shown to induce transformation of SMCs 
into foam cells and to be mediated by the LDL receptor-dependent pathway [155]. In addition, 
LDL-derived aggregates and small lipid droplets, which are potent inducers of massive CE load-
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ing of macrophages, have been shown to be taken up by the LDL receptor-dependent pathway by 
the macrophages [119;209;267;305].
5.2.2. LDL receptor-related protein (LRP)-mediated uptake of LDL
In the arterial intima, LDL-derived lipid droplets are associated with ECM. It has been shown 
that uptake of matrix-retained and aggregated LDL by macrophages [231] and versican-treated 
aggregated and fused LDL by SMCs [155] was mediated by LRP. In fact, an LRP-mediated path-
way has been shown to have a major role in the uptake of aggregated LDL by SMCs [154] and it 
may involve cell surface HSPGs [153]. In addition, differentiated macrophages have been shown 
to express LDL receptor poorly [316] whereas expression of LRP is highly up-regulated in both 
macrophages and SMCs in vivo in the atherosclerotic lesions [57;93;164]. Moreover, expression 
of LRP is upregulated by accumulation of intracellular CE in SMCs [156] suggesting that LRP 
could be one of the most important receptors that mediate the formation of foam cells in the arte-
rial intima. 
5.2.3. Scavenger receptor (SR)-mediated uptake of LDL
Modified LDL particles can also be taken up by charge- and motif-based receptors, such as SRs. 
OxLDL, which has a negative net charge due to modification of positively charged lysine and 
arginine residues in apoB-100 and/or accumulation of electronegative molecules, such as FFAs, 
is taken up avidly by SRs, but it is rather poor in inducing formation of foam cells. However, 
aggregated oxLDL particles have been shown to induce formation of cytoplasmic lipid droplets 
in macrophages [10]. The authors suggested that the primary receptor for aggregated oxLDL in 
macrophages is SR A, whereas non-aggregated oxLDL is taken up mainly by other SRs than SR 
A [9]. The likely candidate receptor for the non-aggregated oxLDL is CD36, a type B SR, that 
has been shown to participate in the uptake and degradation of moderately oxidized LDL [65]. In 
fact, lipid-laden macrophages have been shown to exhibit strong immunoreactivity to CD36, but 
only low or moderate levels of immunoreactivity to SR A [183], suggesting that CD36 could be 
the predominant macrophage receptor for oxLDL in human atherosclerotic lesions. 
5.2.4. Intracellular accumulation of UC
Normally, receptor-mediated uptake of LDL results in complete hydrolysis of its lipid and protein 
components by lysosomal acid hydrolases, such as cathepsin D and lysosomal acid lipase (LAL). 
From lysosomes, liberated cholesterol enters the cytoplasmic metabolically active pool of UC 
[27] and is transported either to the plasma membrane or directly to the endoplasmic reticulum 
[287]. As described below, excess of UC has deleterious effects in the cellular membranes, and 
therefore, it has to be eliminated. In the cytoplasm, UC is re-esterified by acyl coenzyme A:cho-
lesterol acyl-transferase and stored as cytoplasmic CE droplets. Cytoplasmic CE droplets, on the 
other hand, can be hydrolyzed by neutral CE hydrolase, which together with acyl coenzyme A:
cholesterol acyl-transferase can create a constant futile cycle of hydrolysis and re-esterification 
of cholesterol.  
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In addition to cytoplasmic lipid droplets, cholesterol can accumulate in lysosomes. For example, 
oxLDL is avidly taken up by SRs, but is rather poor in inducing the formation of cytoplasmic CE 
droplets in vascular cells. The likely reason is poor degradation of oxLDL particles in lysosomes. 
ApoB-100 in oxLDL has been shown to be resistant to degradation by cathepsins, especially 
cathepsin B, but not cathepsin D [37;98]. In addition, formation of oxysterols [166] or mere lyso-
somal accumulation of UC [219] has been shown to inhibit lysosomal SMase activity and to lead 
to accumulation of SM that can disrupt normal peripheral cholesterol distribution [145] and may 
lead to expansion of lysosomes [160].
 
UC can also accumulate in cellular membranes, where it can have an influence on the function of 
cellular receptors [78;309]. The plasma membrane is normally enriched in UC, i.e. it contains 65-
80% of the total cellular cholesterol [150;171;212], but a unphysiologically high UC/phospholipid 
ratio can inhibit the function of some integral membrane proteins, such as NA+-K+ ATPase and 
adenylate cyclase [309], and the function of cholesterol efflux proteins, such as ATP-binding cassette 
transporter A1[67]. In contrast, the endoplasmic reticulum is low in cholesterol [26] and normally 
contains only a few percent of the total cellular cholesterol [150;171;212]. Thus, excess of the UC 
in the internal membranes may interfere with integral membrane proteins, induce apoptosis of the 
cells [68], and induce a pro-inflammatory response in the cells [146]. 
5.2.5.  Removal of excess cellular cholesterol
Because most of the extrahepatic cells in the body cannot degrade excess cholesterol, it must be 
released from these cells to be conveyed to the liver for excretion from the body (“reverse choles-
terol transport”). UC from lysosomes is first delivered to the plasma membrane, possibly into rafts, 
which concentrate cholesterol and sphingolipids within the plasma membrane microdomains or 
caveolae, where the cholesterol efflux process is driven by the presence of extracellular acceptors 
of UC. Also the UC molecules derived from cytoplasmic CE droplets can be transported to the 
plasma membrane. From the plasma membrane, there are three distinct pathways for cholesterol 
efflux: passive diffusion, SR-B1-mediated selective efflux, and ATP-binding cassette transporter-
mediated efflux. Passive diffusion of cholesterol is driven by the ratio of cholesterol to phospholipid 
of the acceptor(s) vs. the plasma membrane, as well as by the lipid composition of the plasma 
membrane [204]. SR-B1 can bind HDL and phospholipid acceptors of cholesterol [48;110] and 
has the greatest affinity to large HDL particles [148]. SR-B1 is localised to caveolae and expres-
sion of this protein in different cell lines or transfected cells correlates with rates of UC efflux to 
HDL [110]. ATP-binding cassette transporter A1, which is required for uptake of lipid by the cells 
[179], mediates efflux of cellular phospholipids and cholesterol to pre-β-HDL, comprising lipid-
poor apolipoproteins, such as apoA-I [69;196;292], but interacts poorly with the mature globular 
HDL
2
 and HDL
3
 particles [292;293] which constitute the bulk of the plasma HDL pool. In contrast, 
ATP-binding cassette transporters G1 and G4 have been shown to mediate cholesterol efflux to 
HDL
2
 and HDL
3
, but not to lipid-poor apoA-I [291]. Thus, virtually all the HDL subpopulations 
and most HDL apolipoproteins are able to function as acceptors of cholesterol.
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5.3. Secretion of pro-inflammatory cytokines from vascular cells 
Atherogenesis is characterized by the expression and secretion of cytokines in the arterial intima. 
Cytokines are low molecular weight proteins that regulate various cellular functions such as migra-
tion, differentiation, and proliferation. In atherosclerotic lesions numerous different cytokines are 
secreted by the vascular cells. These include both anti-inflammatory cytokines such as interleukin 10 
(IL-10) and transforming growth factor β, and pro-inflammatory cytokines such as tumor necrosis 
factor α (TNF-α), IL-1, IL-8, IL-6, and monocyte chemoattractant protein 1 (MCP-1). Secretion of 
cytokines by vascular cells is in part mediated by the mitogen activated protein kinases (MAPKs). 
Mammalian MAPK signal transduction pathways include the extracellular signal-regulated kinase 
1 and 2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 MAPK. Especially the p38 pathways 
have been shown to play an important role in the expression of several cytokine and chemokine 
genes [195;203]. In addition, promoter regions of many of the pro-atherogenic cytokines, such as 
IL-8, have been shown to contain consensus binding sites for transcription factors nuclear factor 
kappa B (NF-κB) and activator protein 1 (AP-1) [223]. In fact, it seems that concurrent operation 
of AP-1 and NF-κB is required for the transactivation of inflammatory genes, such as the IL-8 gene. 
The roles in atherosclerosis of the most common chemokines for monocytes, i.e. MCP-1, IL-8, and 
pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-1β, are reviewed shortly here.
5.3.1. TNF-α and IL-1β in atherosclerosis
TNF-α and IL-1β are two pro-inflammatory cytokines that have a wide range of pro-atherogenic 
activities. For example, by inducing expression of leukocyte adhesion molecules on ECs, increas-
ing EC permeability, and by inducing secretion of pro-inflammatory cytokines, such as MCP-1and 
IL-8 by ECs, they can accelerate immigration of monocytes into the arterial intima (Reviewed by 
Pober & Cotran (1990)) [207]. TNF-α and IL-1β have also been shown to be secreted by ECs, 
macrophages, and SMCs, and have been detected in human atherosclerotic plaques in vivo (Re-
vieved by Saadeddin et al. (2002)) [230].
5.3.2. MCP-1 and IL-8 in atherosclerosis
MCP-1 and IL-8 are chemotactic cytokines, chemokines, that are released by vascular cells in re-
sponse to TNF-α and IL-1β. They have been shown to participate in the recruitment of monocytes 
and T-lymphocytes to the atherosclerosisprone sites of the arterial wall [76]. MCP-1 has been 
shown to be expressed by macrophages, SMCs, and ECs [185;274;313], whereas IL-8 is produced 
mainly by macrophages [7;294] in human atherosclerotic lesions. The importance of MCP-1 and 
IL-8 in atherogenesis have been confirmed by experiments with atherosclerotic animal models. 
Thus, blocking of the function of MCP-1 [80;188] or deletion of its receptor (CC-chemokine recep-
tor 2) [25;60] have been shown to attenuate atherosclerosis in mice. In addition, transplantation 
of bone marrow cells from mice overexpressing MCP-1 into irradiated apoE-knockout mice [2] 
or from mice lacking the IL-8 receptor (CXC-chemokine receptor 2) into LDL receptor-deficient 
mice [21], led to increased or decreased atherosclerosis, respectively, suggesting that MCP-1 and 
IL-8 play significant roles in atherogenesis. 
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5.3.3. IL-6 in atherosclerosis
IL-6 is a multifunctional cytokine, that can promote differentiation of monocytes to macrophages 
[52] and can induce proliferation of SMCs in vitro [182]. Expression of IL-6 has been detected in 
atherosclerotic lesions of human tissues [121;228;238], in hypercholesterolemic rats [104], and in 
apoE-deficient mice [269] and it was found to colocalize with macrophages [238;269] and SMCs 
[121].  Moreover, ECs have been shown to be able to secrete IL-6 in response to an inflammatory 
stimulus in vitro [181] suggesting that most of the vascular cell types can be induced to secrete 
IL-6. In addition, higher levels of IL-6 have been shown to correlate positively with the extent of 
coronary atherosclerosis [66] and myocardial infarction [105;221]. Thus, IL-6 seems to be strongly 
associated with atherosclerosis.
5.3.4. Secretion of pro-inflammatory cytokines by LDL-treated vascular cells 
High plasma concentration of LDL cholesterol is the principal risk factor in atherosclerosis. Ac-
cording to the prevailing hypothesis, i.e. the response-to-retention hypothesis, increased retention of 
LDL in the PG rich layer of arterial intima promote transformation of LDL particles into atherogenic 
moieties. However, it has been recently shown that even native LDL was able to induce activation of 
both ERK1/2 and p38 MAPKs, nuclear translocation of AP-1 but not NF-κB, and secretion of IL-8 
from SMCs [229]. Moreover, blocking of IL-8 release by SB203580, a specific inhibitor of p38, 
but not with PD98059, an inhibitor of ERK1/2, has shown that the expression of IL-8 is mediated 
by p38 MAPK. Activation of SMCs by LDL has been suggested to involve a rather nonspecific 
second messenger, such as modulation of the cellular redox balance [157]. Indeed, LDL has been 
demonstrated to give rise to the reactive oxygen species, such as H
2
O
2
, in SMCs [229]. Therefore, 
by inducing secretion of IL-8, a chemoattractant of SMCs [318] and monocytes [76], LDL could 
promote accumulation of SMCs and monocytes in the atherosclerotic intima. 
5.3.5. Secretion of pro-inflammatory cytokines by cells treated with   
          enzymatically-modified LDL
Modifications that induce aggregation and fusion of LDL, i.e. lipolysis, proteolysis, and oxidation 
of LDL dramatically increase the ability of LDL to induce secretion of pro-inflammatory cytokines 
from vascular cells. Atherogenic properties of PLA
2
-treated LDL are partly mediated by the prod-
ucts of the enzymatic activity of PLA
2
, lysophospholipids and FFAs. These lipid mediators can be 
delivered into the arterial cells either by the PLA
2
-modified lipoproteins themselves or by albumin, 
where they can induce functional alterations of the cells. It has been suggested that PLA
2
 could 
modify lipoproteins already in the blood plasma compartment [235]. In that case, FFAs and LPCs 
would be delivered first to ECs. Both LPC and FFA have been shown to induce secretion of IL-8 
[270;272], IL-6 [259;272] and MCP-1 [273] from ECs in vitro (Table III). In addition, FFA [259] 
and LPC [225] induce secretion of IL-6 and MCP-1, respectively, from SMCs.
An increased level of palmitate in plasma [259] and an increased  proportion of palmitate and 
linoleate in phospholipids in atherosclerotic coronary arteries [163] have been correlated with the 
concentration of pro-inflammatory cytokines in the circulation and the severity of coronary heart 
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Stimulus   Cytokine Cell type  Reference
OxLDL   IL-8  EC      [54]
   IL-8  mono, macrophage  [276]
 [294]
   IL-8  SMC    [229]
   IL-1β  macrophage   [133]
  IL-1β  SMC    [149]
mm-LDL IL-6  macrophage   [177]
MCP-1  EC, SMC     [56]
  MCP-1  macrophage   [177]
  MCP-1  EC, SMC   [184]
  TNF-α  macrophage   [177]
OxPAPC MCP-1, IL-8 EC    [310]
 [140]
 POVPC, PGPC, MCP-1, IL-8 EC    [140]
PEIPC, PECPC        [266]
 7β-hydroxy-  IL-1β  EC    [144]
cholesterol, 
 7-ketocholesterol 
HOCL-LDL IL-8  mono    [302]
PLA
2
-LDL  MCP-1, IL-8 EC    [15]
   IL-8  mono    [276]
LPC   MCP-1  EC, SMC   [273]
          [225]  
   MCP-1  EC    [254]
   IL-8, IL-6 EC    [272]
   IL-1β  mono    [151]
FFA   IL-8  SMC        [3]
   IL-8  EC    [270]
         [317]
   IL-6  EC, SMC   [259]
LDL(-)   MCP-1, IL-8 EC      [61]
 [232]
E-LDL   MCP-1, IL-6 macrophage, SMC  [123]
         [124]
   IL-8  EC    [270]
nLDL   IL-8  SMC    [229]
acLDL   MCP-1, IL-8 macrophage   [294]
Table III. Release of cytokines from LDL-treated cells. Abbreviations: AcLDL; acetylated LDL, EC; endothelial cell, 
E-LDL; enzymatically modified LDL, FFA; free fatty acid, HOCL-LDL; glycoxLDL; glycoxidized LDL, HOCL-LDL; 
hypochlorous acid-treated LDL, IL-6; interleukin 6, LDL(-); electronegative LDL, LPC; lysophosphatidylcholine, MCP-1; 
monocyte chemoattractant protein 1, mmLDL; minimally-modified LDL, mono; monocyte, nLDL; native LDL, oxPAPC; 
oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, oxLDL; oxidized LDL, PLA
2
-LDL; phospholipase 
A
2
-treated LDL, POVPC; 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine, PGPC; 1-palmitoyl-2-glutaroyl-
sn-glycero-3-phosphorylcholine, PEIPC; 1-palmitoyl-2- epoxyisoprostane-sn-glycero-3-phosphocholine, PECPC; 1-palmi-
toyl-2- epoxycyclopentenone-sn-glycero-3-phosphocholine, SMC; smooth muscle cell, TNF-α; tumor necrosis factor α.
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disease, respectively, suggesting that FFAs play a role in the pathogenesis of atherosclerosis. It has 
been shown in vitro that E-LDL [270] and electronegative LDL [61; 232], both enriched in FFAs, 
induced secretion of IL-8 from ECs. In addition, exposure of ECs to linoleate has been shown to 
induce secretion of IL-8 [270;317] and a significant activation of the NF-kB [90;317], an oxidative 
stress-sensitive transcription factor. Furthermore, secretion of IL-6 and MCP-1 [123;124], both 
oxidative stress-inducible cytokines, from macrophages and SMCs cells suggests that intracellular 
oxidative stress plays a role in the early events in FFA-treated vascular cells. Indeed, elevated FFA 
levels in humans have been shown to induce generation of reactive oxygen species in the ECs and 
in vascular SMCs [107]. 
In addition to FFAs and LPCs, increase in the cellular content of UC has been shown to induce 
secretion of pro-inflammatory cytokines, such as IL-8 [294] and IL-6 [146]. Thus, by inducing 
secretion of IL-8, IL-6 and MCP-1 from cultured vascular cells, LPC, FFA, and UC-enriched LDL 
could promote both accumulation and differentiation of monocytes and SMCs in atherosclerotic 
lesions. 
5.3.6. Secretion of pro-inflammatory cytokines by oxLDL-treated cells
Oxidation of LDL particles generates various biologically active molecules depending on the 
degree of modification. In minimally-modified LDL, active components have been suggested to 
be oxidized phospholipids, such as oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phospho-
choline (oxPAPC). OxPAPC and other other oxidized phospholipid derivatives have been shown 
to increase production of MCP-1 and IL-8 in human aortic EC [140;266], MCP-1 from SMCs 
[56] and macrophages [177], IL-6 from macrophages [177], and to induce expression of TNF-α in 
macrophages [177] (Table III). Extensively oxidized LDL, in which both the lipid and the protein 
moieties of LDL are modified, has been shown to induce secretion of IL-8 from monocytes and/or 
macrophages [276] [294] and from ECs [54], and to induce secretion of IL-1β from macrophages 
[133] and SMCs [149]. 
Activation of signaling pathways are also partly different depending on the extent of oxidation 
of LDL. For example, minimally-modified LDL has been shown to induce activation of p38 and 
JNK MAPKs, but not ERK1/2 MAPK in SMCs [158], but did not induce a nuclear translocation 
of either AP-1 or NF-κB in ECs [310]. In contrast, extensively oxidized LDL has been shown to 
activate ERK1/2 in SMCs [51] and to induce nuclear translocation of NF-κB in SMCs and ECs 
[172]. Thus, oxidation of LDL generates a heterogenous group of chemically and morphologically 
different LDL particles that may have numerous different cellular effects.
5.4. Increased susceptibility of modified LDL to further modifications
5.4.1. Enhancement of LDL modifications by oxidation
In addition to the direct atherogenic properties of aggregated and fused LDL particles, such as 
retention to PGs and induction of cytokine release from vascular cells, particle modifications make 
them more prone to secondary modification by other enzymes or agents. Oxidation, the type of 
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modification most studied in terms of atherosclerotic potential of modified LDL particles, has 
been shown to enhance the lipolytic modification of LDL. Thus, oxidation promotes modification 
of LDL by SMase [239] and by Type IIA sPLA
2 
[63]. Native LDL is a poor substrate for Type IIA 
sPLA
2
, but mild oxidation of LDL has been shown to increase the enzymatic activity of Type IIA 
sPLA
2
 on LDL [63]. The authors suggested that oxidation of unsaturated fatty acid acyl residues 
is responsible, at least partly, for this phenomenon. In fact, there are several reports that oxidized 
phospholipids serve as better substrate for PLA
2 
[246;288] and for the intrinsic LDL-PLA
2
 or 
platelet-activating factor acetylhydrolase (PAF-AH) [258]. However, extensive oxidation of LDL 
is supposed to decrease the lipolytic activity of Type IIA sPLA
2 
on LDL [63] and PLA
2
-treated 
LDL has been shown to be more resistant to oxidation than native LDL [8]. The latter effect was 
reversed by addition of FFAs, suggesting that FFA enriched LDL particles are more suspectible to 
oxidation than native LDL particles. Indeed, FFAs have been shown to increase the oxidizability 
of LDL [16]. Also, CEs of LDL, that normally are protected from hydrolysis, are susceptible to 
cholesteryl esterases if the apoB-100 of the surface is first degraded by oxidation with Cu2+ [43] 
or by proteases, such as plasmin and matrix metalloproteinases [286]. The subsequent degrada-
tion of the core CEs can, then, transform LDL into liposomal-like particles, that are chemically 
and structurally similar to UC-rich lipid particles of atherosclerotic lesions. 
5.4.2. Enhancement of LDL modifications by PGs
Mere binding to PGs or GAGs can enhance modification of LDL. It has been shown that revers-
ible interactions with CSPG increase the uptake and degradation of LDL by human macrophages 
[103] and SMCs [23;155]. Moreover, susceptibility of LDL to Cu2+ or to cell mediated oxidation, 
as well as uptake by macrophages was enhanced by reversible interaction of LDL with arterial 
CSPG or chondroitin-6-sulfate GAG [100]. The authors have suggested that GAGs increased the 
access of Cu2+ to hydrophobic chromophores and the affinity of Cu2+ to LDL [30]. 
It has also been suggested that the pattern of proteolytic cleavage of apoB-100, which is an im-
portant determinant of the binding reaction between LDL and PG, depends on whether or not the 
particles are immobilized during proteolysis. However, the increased rate of proteolysis and fusion 
of LDL particles that were bound to GAGs has been shown to depend on the colocalization of 
the protease and LDL, rather than an increased catalytic activity of the protease [202]. In contrast 
to the above findings, Sartipy et al. have shown that the catalytic activity of Type IIA sPLA
2
 to 
LDL was increased by direct binding of the enzyme to PGs [234;237]. In addition, chondroitin 
sulfate GAGs have been shown to enhance activity of cathepsin K [147]. 
5.4.3. Enhancement of LDL modifications by lipases
Finally, lipolytic enzymes can promote modification of LDL by another lipolytic enzyme or 
by a pro-oxidative enzyme. It has been shown that sSMase, which has an acidic pH optimum, 
cannot degrade LDL at neutral pH unless it is pre-treated with PLA
2 
[239]. In addition, pre-
treatment of LDL with PLA
2
 promotes sSMase-induced aggregation and fusion of LDL [319]. 
On the other hand, SMase can enhance the enzymatic activity of Types IIA and V sPLA
2 
[77] 
and PLA
2
 has been shown to enhance 15-lipoxygenase-induced oxidation of LDL [186;255].
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There is an increasing consensus that retention and accumulation of LDL in the subendothelial layer 
of the arterial intima initiates the atherosclerotic process. The binding strength of native LDL to PGs 
is low, whereas fusion of the particles substantially increases the strength of binding to PGs. Fused 
LDL particles are also taken up avidly by vascular cells, transforming them into foam cells, the hall-
mark of atherosclerosis, and have been shown to induce secretion of pro-inflammatory cytokines. 
On the basis of these findings, we studied the effects of PLA
2
 and secreted lysosomal hydrolases on 
fusion of LDL particles and on their atherogenic properties. The spesific aims of this study were:
1.  To study the effect of Type IIA sPLA
2 
on the structural modification of LDL and the   
     retention of LDL in the human aortic PGs. (Study I)
2.  To study the role of PGs in the fusion of PLA
2
-treated LDL. (Study II)
3.  To study secretion of macrophage-derived lysosomal acid hydrolases and their effect   
     on extracellular modification of LDL. (Study III)
4.  To study the cellular effects of hydrolase-modified LDL (H-LDL). (Studies III and IV)
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The biochemical methods central to this thesis, cell cultures, and tissue materials used in the original publications are summarized in Table IV. 
Method Original publication Reference
Preparation and labeling of LDL I, II, III, IV [22;88;215]
Extraction and purification of proteoglycans I [101;321]
Protein assays:                  Lowry method
                                          RC DC Protein Assay kit
I, II, III, and IV
IV
[161]
Modification of LDL with:
                                          Type II sPLA2
                                          Type III sPLA2
                                          Lysosomal acid
                                          hydrolases
                                          thrombin
                                          kallikrein
                                          pronase
                                          acetic anhydride
I
II
III
III
III
III
III [14]
TCA-precipitation II, III, and IV [205]
Immunodepletion III
High performance thin-layer chromatography I, II, and III
Gel filtration chromatography II [319]
Affinity chromatography I [198]
Electron microscopy I, II, and III [201]
Microtiter well binding assay I
Ultracentrifugation:          Rate-zonal flotation
                                          Equilibrium density gradient
I
III and IV
[209]
[201]
Determination of TBARS I, III, and IV [91]
Gel electrophoresis:         Cellulose acetate
                                          Agarose
                                          SDS-PAGE
II
III
II, III, and IV
Cultivation and differentiation of the cells:
                                          Mouse peritoneal
                                          macrophages
                                          Human monocytes
                                          HCASMCs
                                          HCAECs
III
III and IV
III and IV
IV
[141]
[233]
Oil Red O staining III
cDNA array (GEArray) IV
RT-PCR IV
Determination of cytokine levels with ELISA kits IV
Determination of FFAs with NEFA kit I, II, and III
Electrophoretic mobility shift assay IV
Immunoblotting IV
Segments of human coronary arteries III
Immunohistochemistry III
Statistical analysis III and IV
Table IV. The methods, cell cultures, and tissue materials used in the study. Abbreviations: ELISA; enzyme-linked 
immunosorbent assay, FFA; free fatty acid, HCAEC; human coronary artery endothelial cell, HCASMC; human coro-
nary artery smooth muscle cell, LDL; low density lipoprotein, RT-PCR; reverse-transcriptase polymerase chain reaction, 
SDS-PAGE; sodium dodecyl sulfate polyacrylamide gel electrophoresis, sPLA2; secretory phospholipase A2, TBARS; 
thiobarbituric acid-reactive substances, TCA; trichloroacetic acid.
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1. Preparation and labeling of LDL
Human LDL (d = 1.019-1.050 g/ml) was isolated from the fasting plasma of healthy volunteers by 
sequential ultracentrifugation under aseptic conditions in the presence of 3 mM EDTA [88;215]. 
LDL was dialyzed to a buffer containing 1 mM EDTA and 150 mM NaCl (pH 7.4) (lipoprotein 
buffer), sterile filtered, and stored at 4°C. Each LDL preparation was prepared from plasma of one 
healthy person and several LDL preparations from different donors were used during the studies. 
Purity of LDL preparations was judged by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and cellulose acetate electrophoresis. LDL which appeared as a single band in cellulose 
acetate electrophoresis and contained only apoB-100 in sodium dodecyl sulfate polyacrylamide 
gel electrophoresis, was used in experiments. Oxidation of LDL was not found during the storage 
as analyzed by TBARS assay. ApoB-100 of LDL was labeled with the tritium-labeling reagent 
by the Bolton-Hunter procedure [22]. The amount of LDL is expressed in terms of its protein 
concentration determined by the method of Lowry [161].
2. Extraction and purification of aortic PGs 
To avoid significant post-mortem autolysis of the arterial tissues [314], human aortas were obtained 
at autopsy within 24-48 h of accidental death. Proteoglycans from intima-media of the aortas were 
isolated as described previously [101;321]. Briefly, PGs were extracted from the intima-media at 
4°C for 24 h with 15 volumes of buffer containing 6 M urea and protease inhibitors. After extrac-
tion, the mixture was centrifuged at 100,000g for 60 minutes. The supernatant was diluted with 6 
M urea to give a final concentration of 0.25 M NaCl and loaded on a HiTrap Q column. The PGs 
were eluted with a linear gradient of 0.25 to 1.0 M NaCl and the peaks at 280 nm were collected, 
dialyzed against water, lyophilized, and stored at -70°C. The disaccharide composition of the PGs 
was analyzed by high performance liquid chromatography using 5-µm NH
2
 column after treatment 
of the PGs with chondroitinase ABC and AC [165]. The PG preparation used contained 49% of 
chondroitin 6-sulfate, 34% of chondroitin 4-sulfate, and 17% of dermatan sulfate.
3. Modifications of LDL  
Human recombinant Type IIA sPLA
2 
was a kind gift from Eva Hurt-Camejo. Tritium-labeled LDL 
(1 mg/ml) was incubated with or without (control) Type IIA sPLA
2
 (7.5 µg/assay) in the presence of 
PGs that were immobilized to NHS-activated Sepharose according to manufacturer’s instructions 
(GE Healthcare). After incubation, the PG-Sepharose-bound tritium-labeled LDL was detached 
with a buffer containing 0.5 M NaCl.
LDL (1 mg/mL) was incubated with or without (control) bee venom PLA
2
 (Type III sPLA
2
) (50 
ng/ml) either in the fluid phase or immobilized into the heparin-Sepharose HiTrap column (GE 
Healthcare) at a physiological salt concentration and pH, and in the presence or absence of 2% 
(w/v) of BSA (Sigma).
For preparation of macrophage-conditioned medium containing hydrolytic enzymes, Zymosan A 
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(Sigma) was opsonized (Zop), i.e. was coated with iC3b and immunoglobulins [50] with fresh hu-
man serum and used for stimulation of human monocyte-derived macrophages. Detached cells and 
Zop-particles were removed from the macrophage-conditioned medium. H-LDL was prepared by 
incubating tritium-labeled LDL (20 µg, 2000 dpm/µg) with the macrophage-conditioned medium 
from Zop-treated macrophages under aseptic conditions at low pH (4.5) for 18-24 h. Control LDL 
was prepared by incubating LDL with the macrophage-conditioned medium from untreated mac-
rophages. After the incubation, both LDL preparations were purified by discontinuous equilibrium 
density gradient ultracentrifugation as described previously [201].   
For the analysis of the enzyme activities in the macrophage-conditioned media, tritium-labeled 
LDL (20 µg, 2000 dpm/µg) was modified in 175 µl of macrophage-conditioned medium (H-
LDL) or control medium (control LDL) in the presence of one of the following inhibitors: 1 mM 
phenylmethylsulfonylfluoride, 10 mM EDTA, 1 µM 4-Morpholineurea-Leu-HomoPhe-vinylsul-
phone (Axys Pharmaceuticals), 30 µM pepstatin A, 4 µM leupeptin, 0.3 µM aprotinin, or 60 nM 
α
2
-macroglobulin. After incubation for 6 h, the degree of apoB-100 degradation was determined 
by measuring the amount of trichloroacetic acidsoluble radiolabeled apoB-100 fragments. For 
immunodepletion experiments, medium from Zop-treated cells and polyclonal rabbit anti-human 
cathepsin D (1µg) (DAKO) or rabbit antiserum against human LAL (5 µl) were mixed and incubated 
at room temperature for 30 min. Protein A-sepharose (35 µl) (Zymed Laboratories) was washed 
and suspended (1:1) with Dulbecco’s Minimal Essential Medium. Aliquots of protein A-sepharose 
(10 µl) suspension were mixed with media and rotated for 30 min at room temperature. After cen-
trifugation at 10,000g for 5 min, the supernatants were collected and used for LDL incubations. 
After the incubations, the degrees of apoB-100 proteolysis and of the lipolytic modifications of 
LDL were determined by the trichloroacetic acid precipitation method and by high performance 
thin layer chromatography, respectively.
LDL was also proteolyzed by thrombin (15 U/ml), kallikrein (4.6 U/ml), and pronase (20 µg/ml) for 
the indicated times and analyzed in sodium dodecyl sulfate polyacrylamide gel electrophoresis. 
LDL was acetylated by repeated additions of acetic anhydride [14], sterile filtered, and stored in 
lipoprotein buffer (see preparation of LDL) at 4°C. The degree of acetylation was monitored by 
cellulose acetate electrophoresis.
4. Analysis of modified LDL 
The degree of aggregation and/or fusion of the LDL samples was determined by gel filtration 
chromatography at 4°C. Samples (100-400 µg of LDL) were run through a Superose 6 HR 10/30 
column (GE Healthcare) and fractions were collected. The degree of aggregation and/or fusion of 
the LDL samples was determined by calculating the ration of the radioactivity in the void volume 
peak to the total amount of radioactivity eluted. The function of the column was monitored by 
following the pressure values during the runs, the ratio between applied and eluted radioactivity, 
and the elution time of native and/or untreated LDL. For the rate-zonal flotation [209] NaBr was 
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added to 500 µl of modified tritium-labeled LDL to yield 40% NaBr (w/v). Linear NaBr gradi-
ent (d=1.006 to 1.10 g/ml) was layered on the top of each sample and centrifuged at 33,000 rpm 
in a SW 40 Ti rotor (Beckman) for 1 hour at 20°C. The gradient was then fractioned into 500 µl 
aliquots, the radioactivities of which were determined. Flotation velocity of modified LDL was 
compared to flotation of untreated LDL. The reliability of the run was judged by following the 
flotation velocity of native or untreated LDL. Aggregation and/or fusion of modified LDL, i.e. 
increased turbidity of the sample, was also analyzed by measuring the absorbance of the reaction 
mixture at 340 nm (III).
The morphology of the modified LDL particles was analyzed by transmission electron microscopy. 
For this purpose, LDL preparations were negatively stained as described previously [72;201]. 
Briefly, LDL samples were dried on the grid coated with a thin carbon film, stained with 1% 
of potassium phosphotungstate (pH 7.4), and viewed in a JEOL JEM-1200EX or a JEOL JEM-
100CX transmission electron microscope. For the determination of the size distribution of the 
LDL particles, the diameters of 200 randomly selected lipoprotein particles were measured from 
the electron micrographs. In addition, some samples were analyzed in thin-section transmission 
electron microscopy as described [201]. Briefly, LDL samples were cast into 2% GTG low-melting 
point agarose gel and fixed with 3% of glutaraldehyde at 4°C for 18 h. Fixed samples were stained 
with osmium-tannic-acid-paraphenylenediamine technique as described [81] and processed for 
electron microscopy. Diameters of the modified LDL particles were compared to native and/or 
untreated LDL.
The binding strength of the control and modified LDL to PGs were analyzed by affinity chromatog-
raphy as described [198]. Aliquots (20-30 µg) of the PLA
2
-modified LDL samples were dialyzed 
against buffer B (10 mM Hepes, 5 mM CaCl
2
, 2 mM MgCl
2
, pH 7.4) containing 20 mM NaCl, 
applied to PG affinity columns, and eluted with a linear NaCl gradient (20-250 mM) in buffer B 
at a flow rate of 0.5 ml/min. Elution was monitored by UV absorbance at 280 nm. Fractions (200 
µl) were collected and their radioactivities were determined by liquid scintillation counting. The 
chromatographic apparatus was SMART (Amersham Pharmacia Biotech). The typical binding 
strength of the control LDL to PGs served as the measure of the quality of PG-Sepharose columns. 
Accumulation of the control and modified LDL in immobilized PGs was analyzed in the wells of 
polystyrene 96-well plates that had been coated with 100 µl of human aortic PGs (50 µg/ml) or 
bovine serum albumin (5 mg/ml) by incubation at 4°C overnight. Tritium-labeled LDL  (5 µg) was 
incubated with or without (control) human recombinant Type IIA sPLA
2
 (0.5 µg) in the wells for 
6 h at 37°C, and the amount of radioactivity retained in the PG-coated wells was determined with 
a scintillation counter. Spesific binding to PGs was calculated by subtracting the amount of LDL 
bound to BSA-coated wells from the amount of LDL bound to PG-coated wells.
The lipid composition of the LDL preparations was analyzed from lipid extracts [20] by high per-
formance thin layer chromatography, using chloroform/methanol/concentrated acetic acid/H
2
O (50:
30:8:3.5, v/v/v/v) for phospholipids and hexane/diethylether/concentrated acetic acid/H
2
0 (130:30:
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2:0.5, v/v/v/v) for neutral lipids. Individual lipid classes were visualized by dipping the thin layer 
chromatography plate into CuSO
4
 (3%)/H
3
PO
4
 (8%) and then charring the plates in the heater at 
150°C. The spots were scanned with an automatic plate scanner (CAMAG TLC Scanner n:o 3). 
The total cholesterol content of H-LDL was also determined with commercial CHOD-PAP kit 
(Roche) (IV) and the generation of FFAs was measured with NEFA C kit (Wako) according to 
manufacturer’s instructions.
 
The degree of LDL oxidation was determined by measuring the amount of thiobarbituric acid-
reactive substances [91]. The net charge of oxidized and acetylated LDL particles was analyzed 
by cellulose acetate electrophoresis and agarose gel electrophoresis, and the spots were visualized 
with Ponceau-S or Sudan Black, respectively.
The degree of proteolysis of LDL was determined by measuring the trichloroacetic acidsoluble 
apoB-100 radioactivity as described [205]. The integrity of apoB-100 was analyzed by sodium 
dodecyl sulphate polyacrylamide gels (4-20%) under reducing conditions [136]. The gels were 
stained with Coomassie Brilliant Blue and destained with 40% methanol (v/v)-10% acetic acid 
(v/v). 
5. Cell culture
Peritoneal macrophages were harvested from unstimulated NMRI mice (20-30 g, purchased from 
Viikki Laboratory Animal Center of the University of Helsinki) and plated as described [141]. Hu-
man monocytes were isolated from buffy coats obtained from The Finnish Red Cross, Helsinki, as 
described previously [233]. The cells were cultured in macrophage serum-free medium (GIBCO) 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 ng/ml granulocyte-mac-
rophage colony-stimulating factor (Cascade Biologics). The cells were cultured for 7 days to in-
duce differentiation of monocytes into macrophages, and were then used for experiments. Human 
coronary artery SMCs (Clonetics) were seeded on 25 mm2 flasks and cultured in Medium 231 
(Cascade Biologics) supplemented with growth factors and the mixture of antibiotics (penicillin, 
streptomycin, ampicillin). Before experiments growth arrest was induced by incubating the cells in 
growth factor-free medium for 48 h before treatment. Passages 5-8 were used in the experiments. 
Human coronary artery ECs (PromoCell) were plated in flasks (350,000 cells/ 25 cm2) and cultured 
in Endothelial cell basal medium Mv (PromoCell) containing fetal calf serum (5%), endothelial 
cell growth supplement, epidermal growth factor, hydrocortisone, gentamicin and amphotericin 
B. Before stimulation arrest of growth was induced by incubating the cells in growth factor-free 
medium containing 0.5% fetal calf serum for 3 h. Passages 5-8 were used in the experiments. The 
quality of the cells was continuously observed under the microscope.
6. Analysis of the lipid loading of the cells
For Oil Red O staining, macrophages and human coronary artery SMCs were plated on 13-mm 
glass coverslips, loaded with modified LDL for the indicated times, and then stained with 0.7% 
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Oil Red O. The coverslips were mounted on glass microscope slides with Aquamount (BHD 
Laboratory Supplies) and photographed. The cells loaded with native LDL and acetylated LDL 
served as negative and positive controls, respectively. For determination of the lipid loading of 
the cells, cellular lipids were extracted with hexan:isopropanol (3:2, v/v). The samples were then 
dried under N
2
, dissolved in chloroform:methanol (2:1, v:v), and analyzed with high perform-
ance thin-layer chromatography. The cytoplasmic lipid droplets were also visualized by electron 
microscopy. For this purpose, human monocyte-derived macrophages were fixed with 2.5% (v/v) 
glutaraldehyde and postfixed with 2% (v/v) osmium tetroxide. Samples were then stained with 
the tannic acid-paraphenylenediamine technique as described [201] and processed for electron 
microscopy. Untreated cells and acetylated LDLtreated cells served as negative and positive 
controls, respectively.
7. Analysis of the expression and secretion of cytokines in H-LDL-stimu- 
    lated cells 
Human monocyte-derived macrophages, human coronary artery SMCs, and human coronary artery 
ECs were incubated for the indicated times with or without (control) H-LDL (50 µg cholesterol/
ml) and total RNAs were extracted with the Qiagen Minikit (Qiagen), and stored at -70°C, if not 
used immediately. Expression of the common human cytokine genes in H-LDL-stimulated cells 
was analyzed with commercial GEArray Q Series kit (SuperArray Bioscience Corporation, MD, 
USA) according to manufacturer’s instructions. The controls for the assay were included in the kit 
and appeared to be normal in all the assays. RNAs extracted from untreated cells and lipopolysac-
charide-treated cells served as controls for the experiments. For reverse-transcriptase polymerase 
chain reaction analysis of the gene expression, complementary DNAs were synthesized by using 
random primers (50 ng/ml) and MMLV Reverse Transcriptase (Invitrogen). After the synthesis, 
complementary DNAs were cooled to +4°C and stored at -20°C. For the polymerase chain reac-
tion, 1 µl of each complementary DNA was mixed with the reaction buffer containing Tag DNA 
Polymerase. After the polymerase chain reaction the products were analyzed in 1.4% agarose gel 
and quantified with the Gel Doc 2000 gel documentation system.
The quantities of IL-8, IL-6, IL-1 and MCP-1 secreted by H-LDL-treated cells was measured 
in centrifuged cell culture media with commercial enzyme-linked immunosorbent assay kits ac-
cording to the manufacturer’s instructions (Human immunoassays, Quantikine, R&D Systems). 
Sensitivities of the kits (varied from 0.5-7.5 pg/ml) were sufficient to detect the lowest amounts 
of cytokines in our experiments. The coefficiency of variation for the kits varied from 1.7 to 5.9% 
(intra-assay measurements) and from 2.0 to 8.1% (inter-assay measurements) as stated in the data 
sheets of the manufacturer. 
8. Analysis of the signaling molecules in H-LDL-treated macrophages
Human monocyte-derived macrophages were pre-incubated for 30 minutes with or without ap-
propriate inhibitors: 10 µM SB203580 (p38 MAPK), 30 µM PD98059 (ERK1/2 MAPK), 10 
µM JNK inhibitor II (JNK), 15 µg/ml caffeic acid phenethyl ester (NF-κB), 10 µM MG-132 
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(proteasome/NF-κB), 2 µM sulfasalazine (NF-κB), and 10 µM curcumin (AP-1). Concentration 
of the inhibitors that was not cytotoxic to the cells was used in experiments. Then, H-LDL was 
added and incubations were continued for 6h at 37°C. After the incubations, the amount of IL-8 
in the media was analyzed with commercial enzyme-linked immunosorbent assay kit. 
Nuclear extracts for electrophoretic mobility shift assay were produced by the modified method 
of Andrews & Faller [5]. Briefly, the cells were first swelled in ice-cold hypotonic buffer for 10 
minutes, after which NP-40 (final concentration of 0.1%) was added and the cells were vortexed 
for 10 s. After centrifugation, the supernatants were stored at -70°C for Western blotting, and the 
pellets containing the nuclei were resuspended in ice-cold high salt buffer. After incubation for 20 
minutes on ice, the nuclear debris was removed by centrifugation and the supernatant, containing 
nuclear proteins, was stored at -70°C.
Double-stranded DNA oligomers (Santa Cruz) were labeled with [γ-32P]ATP, purified in a Sephadex 
G-50 Nick column (GE Healthcare) and the radioactivity of the labeled oligomers were measured 
with a scintillation counter. 5-10 µg of the nuclear protein extracts were incubated for 10 minutes 
on ice in the reaction buffer, labeled DNA probes (50 000 dpm) were added, and incubation was 
continued for an additional 30-60 minutes at room temperature. Competitors, i.e. non-labeled or 
mutated appropriate oligomers, were added 10 minutes before the labeled probes. For supershift 
assays, the samples were incubated with 2 µg of appropriate antibodies at room temperature for 
an additional 1h. Samples were then mixed with DNA-loading buffer and were run in 4% non-
denaturing polyacrylamide gel. After the electrophoresis, the gel was dried and the bands were 
visualized by autoradiography. Nuclear extracts from untreated and lipopolysaccharide-treated 
cells served as controls for the experiment. Non-labeled and mutated oligomers served as controls 
for the assay.
Phosphorylation of MAPKs was analyzed by immunoblotting. The total cell lysates were run 
in 15% sodium dodecyl sulphate polyacrylamide gel under reductive conditions. The protein 
concentration of the samples was determined by the commercial RC DC Protein Assay kit (Bio 
Rad). The proteins were transferred to polyvinylidine fluoride membranes, and the bands were 
immunostained according to the instructions of Cell Signaling Technology. The bands were visu-
alized with an enhanced chemiluminescense kit (GE Healthcare). The assay was controlled with 
commercial positive and negative controls. In addition, extract from lipopolysaccharidetreated 
cells served as an additional positive control for the assay and for the experiment. The proportion 
of activated (phosphorylated) p38 was estimated by comparing the ration of phosphorylated form 
of p38 to total p38 MAPK.
9. Immunohistochemistry
Segments of human coronary arteries (n= 37) were collected at autopsy in the Department of Fo-
rensic Medicine, University of Helsinki, Helsinki, Finland, or during heart transplantation (n= 4) 
at the Papworth Hospital, Cambridge, U.K. The samples were either embedded in OCT medium 
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and snap-frozen in liquid nitrogen (34 samples) or fixed with 10% neutral-buffered formalin and 
embedded in paraffin (7 samples) according to standard procedure. Sections were cut and im-
munostained with ABC Elite kits from Vector Laboratories (Burlingame, CA) according to the 
manufacturer’s instructions, using 3-amino-9-ethylcarbazole (Sigma) as the peroxidase substrate. 
The sections were then counterstained with hematoxylin and mounted in Aquamount. The samples 
were viewed and photographed with a Nikon E600 microscope with a cooled CCD camera (Spot 
RT, Diagnostic Instruments, Sterling Heights, MI). The primary antibodies used were rabbit anti-
human LAL antiserum (1:300 dilution, a kind gift from Drs Du and Grabowski, Ohio, USA), rabbit 
anti-human cathepsin D antibody (40 µg/ml, DAKO), mouse anti-human cathepsin D antibody (10 
µg/ml, Calbiochem), and mouse anti-human CD68 (7.2 µg/ml, DAKO). As negative controls, the 
primary antibodies were replaced with non-specific rabbit IgG or isotype-matched mouse IgG. 
10. Other determinations 
The cytotoxicity of the reagents towards the cells was determined by measuring the release of 
lactate dehydrogenase with the Cytotoxicity Detection Kit  (Roche) (IV) according to the manu-
facturer’s instructions. The bacterial endotoxin contamination in the H-LDL preparations was 
monitored with Limulus Amebocyte Lysate kit (Bio Whittaker) according to the manufacturer’s 
instructions (IV).
 
11. Statistical analysis 
Results of individual experiment, or means ±S.E.M. of the given number of experiments are shown. 
The data were analyzed with the two-tailed unpaired Student’s t test; p< 0.05 was considered 
statistically significant.
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1. Type IIA sPLA2 induces fusion of LDL particles and  
    increases their binding strength for human PGs.
A variety of enzymes and agents have been shown to induce aggregation and fusion of LDL in vitro, but only a few of them are expressed in the arterial intima. A Type IIA sPLA
2
 is an 
enzyme that has been shown to be located extracellularly in the intima [99;174;224]. It is capable 
of lipolyzing LDL [236] and GAGs can increase the activity of Type IIA sPLA
2 
toward LDL [234]. 
Thus, we lipolyzed LDL with human Type IIA sPLA
2 
in the presence of human aortic PGs. We 
found that the binding strength of lipolyzed LDL particles for the human aortic PGs was increased 
substantially (Study I, Fig. 3A). In contrast to the results of Hurt-Camejo et al. (1997), all the 
lipolyzed particles, that had increased binding strength for PGs, appeared to be fused (Study I, Fig. 
2 and 3B). Thus, the mean diameter of the particles that had been bound to PGs during lipolysis 
(32 nm ± 6 nm, median 32 nm) was larger than unlipolyzed PG-bound particles (23 nm ± 3 nm, 
median 22 nm) which resembled native LDL (22 nm ± 4 nm, median 22 nm) as analyzed by elec-
tron microscopy. In addition, by using immobilized PGs, we could show, that lipolysis of LDL 
with Type IIA sPLA
2
 increased the retention of LDL particles to PGs, i.e. induced accumulation of 
lipolyzed LDL in the PG matrix (Study I, Fig. 4). Similar results were obtained with decorin PG 
(Hakala et al. unpublished data). Accumulation of LDL in the PG matrix depended on the degree 
of lipolysis (Hakala et al. unpublished data) suggesting that the effect was induced by Type IIA 
sPLA
2
. These result are in accordance with previous results showing that fusion of LDL increase 
the affinity of LDL to GAGs and PGs [198;319]. All the rection mixtures were tested for oxidation 
and proteolysis of LDL, but no signs of either were found, suggesting that lipolysis of LDL was the 
predominant type of modification of the particles. Thus, lipolysis of LDL with Type IIA sPLA
2
 in 
the presence of human aortic PGs induced fusion of the particles, increased their binding strength 
for PGs, and induced accumulation of the fused particles in the PG matrix.
2. Interaction of LDL with glycosaminoglycans (GAGs)  
     is a prerequisite for fusion of LDL particles
As described previously, the enzymatic activity of Type IIA sPLA2 toward LDL was increased by GAGs [236] and lipolysis of LDL with Type IIA sPLA
2 
induced formation of small dense 
LDL particles [235], whereas in the presence of PGs, all the PG-bound LDL particles that were 
lipolyzed with Type IIA sPLA
2
 appeared to be larger than untreated particles, i.e. they were fused 
(Study I, Fig. 2 and 3B). To study more closely the effect of GAGs and PGs on the lipolysis of 
LDL with PLA
2
, LDL was lipolyzed with or without (control) bee venom PLA
2
 (Type III sPLA
2
) 
in the presence or absence of heparin GAG. We found, that Type III sPLA
2
 induced aggregation 
of about 45% of the heparin-bound LDL particles, 50% of them being larger than any of the un-
treated particles revealing fusion of the particles (Study II, 2E-H). In addition, increased tendency 
of aggregated and/or fused LDL to bind unspesifically to the column may have underestimated 
the proportion of larger LDL particles.  In the absence of heparin, however, only aggregation, but 
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not fusion of the particles was found (Study II, Fig. 1) (Figure 9). The degree of lipolysis and the 
degree of the morphological modifications of LDL were identical in all the LDL preparations, 
i.e. heparin-bound, heparin-treated, and untreated LDL (Study II, Fig. 3), thus, differences in the 
enzymatic activity could not explain the effect. Surprisingly, even a transient interaction of LDL 
with heparin before lipolysis promoted fusion of a fraction of the particles (Study II, Fig. 2A-D) 
suggesting that interaction of LDL with heparin had induced irreversible changes in the structure 
of LDL which then promoted fusion of the LDL particles. Indeed, intertwinement of GAGs and 
proteins has been shown to induce conformational changes in the protein backbone [168] and to 
induce changes both in the conformation of apoB-100 and in the distribution of lipid pools within 
LDL [32;49;170]. Therefore, our results suggest that in addition to loosening of the structure of LDL, 
heparin GAG could perhaps resist the compensatory changes in apoB-100 conformation during 
lipolysis and allow more hydrophobic core lipids to penetrate to the surface of the particles, and 
so facilitate the fusion of some of the adjacent particles. However, we cannot state if aggregation 
and/or fusion of lipolyzed LDL occurred already when the particles were bound to heparin GAG 
or after the detachment of the particles with high salt. In fact, it has been shown [155;283] that 
irreversible changes induced by GAGs in apoB-100 appeared to be so marked that a prolonged 
interaction of LDL with PGs or GAGs, and subsequent removal of the PGs and GAGs from the 
incubation system, induced aggregation of a fraction of the LDL particles [34]. 
+ PLA2
LDL
A. B.
Figure 9. The effect of proteoglycans on fusion of PLA2-treated LDL particles.
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The central observations in Studies I and II, i.e. aggregation and/or fusion of lipolyzed LDL particles 
analyzed by rate-zonal flotation (Study I, Fig. 1) and by gel filtration chromatography (Study II, 
Figs. 1 and 2) were confirmed by repeating the experiments three times. In all the other experiments 
where controls appeared to be normal, two independent and similar results were considered as a 
reliable observation. At that time, we lacked stable spesific quality control specimens that would 
have increased the credibility of the methods. Therefore, the reliability of the assays was judged 
by following the values of control samples, e.g. elution time and flotation velocity of the control 
LDL in affinity chromatography and in rate-zonal flotation, respectively, which usually resembled 
that of native LDL and were extremely repeatable. 
3. Fusion of LDL increases the number of active   
    lysines in PLA2-treated LDL particles
Binding of LDL to PGs is governed by ionic interaction between positively charged lysine and arginine residues of apoB-100 and negatively charged carboxyl and sulfate groups of PGs 
[33;36;108;295]. The lysine residues in apoB-100 are of two type, i.e. normal and active lysine 
residues, the active lysines being involved in the binding of LDL to PGs [162;198;321]. We have 
found that lipolysis of LDL with Type III sPLA
2
 in the presence of heparin increased both the 
amount of active lysines per fused LDL particle and the binding strength of LDL for human aortic 
PGs and heparin (Hakala et al. unpublished data). This is in accordance with the previous results 
that fusion increases the amount of active lysines and the binding strength of SMase-treated LDL 
[319] and α-chymotrypsin-treated LDL [198] for PGs. However, the number of active lysines in 
aggregated Type III sPLA
2
-treated LDL particles did not change (Hakala et al. unpublished data) 
[319], suggesting that the higher binding strength of the aggregates was due to colocalization 
of active lysine residues in aggregates. Surprisingly, the amount of active lysines of monomeric 
lipolyzed particles dropped dramatically in the presence of heparin (Hakala et al. unpublished data), 
whereas in the absence of heparin such an effect has not been found [319]. This was accompanied 
by a decrease in the diameter and binding strength for heparin of monomeric lipolyzed particles 
(Hakala et al. unpublished data). However, this experiment was performed only once and should be 
repeated. Taken together, lipolysis of LDL with Type III sPLA
2
 in the presence of heparin dramati-
cally decreased the amount of active lysine residues in monomeric lipolyzed particles suggesting 
that the decrease in the diameter of monomeric lipolyzed LDL particles had induced substantial 
conformational changes in apoB-100 which partially inactivated the active lysine residues in 
monomeric lipolyzed LDL particles. In contrast, fusion of lipolyzed LDL particles increased the 
amount of active lysines in fused particles and increased their binding strength for PGs and GAGs, 
suggesting that increased retention of the PLA
2
-treated LDL into PG-matrix was due to increase 
in the amount of active lysines in the fused LDL particles. 
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4. Release of LPCs from PLA2-treated LDL particles      allow aggregation of the lipolyzed particles
As discussed above, lipolysis of LDL with Type III sPLA2 in the absence of GAGs or PGs induced aggregation, but not fusion of LDL (Study II, Fig, 1) [319]. The mean diameter of 
all the individual Type III sPLA
2
-treated particles was decreased. Thus, the mean diameters of 
the lipolyzed aggregated and lipolyzed monomeric particles were 18 nm (± 3 nm, median 17nm) 
and 19 nm (± 3 nm, median 18 nm) whereas the mean diameter of control LDL was 22 nm (± 2 
nm, median 23 nm) as analyzed by electron microscopy (Study II, Fig. 1). In addition, all the PC 
molecules in both LDL pools, i.e. aggregated and monomeric particles, were degraded by Type 
III sPLA
2
. Of the formed FFAs, 90% were released from both pools of lipolyzed LDL, whereas 
aggregated particles contained less LPC than monomeric particles (Study II). This result suggests 
that the surface defects on LPC poor lipolyzed particles allow aggregation of the adjacent particles, 
but decrease in the diameter of the extensively lipolyzed particles and the increased rigidity of 
the surface may inhibit subsequent fusion of the particles. Indeed, it has been suggested that the 
release of majority of FFAs and a fraction of LPC from the surface monolayer of the PLA
2
-treated 
LDL induces lipid reorganization, leading to an increase in the proportion of the core lipids in the 
surface [79;159]. This may lead to a more rigid surface lipid environment [159], which may have 
prevented fusion of the lipolyzed particles in our experiments. Interestingly, an increase in the 
rigidity of the surface appears not to take place in LDL that has been treated with either SMase 
or PLC, since the particles readily undergo fusion. Degradation of LDL by SMase and PLC lead 
to release of the hydrophilic phosphocholine molecules, whereas ceramide and DAG are retained 
within the particles [320]. The release of bulky head group (choline) of the phospholipids may 
loosen the surface of LDL and the reaction products, i.e. ceramide and DAG, can form hydropho-
bic surface domains on the LDL particle that can bridge two adjacent particles and induce their 
aggregation and fusion. 
5. Increased negative charge abolishes aggregation  
    and fusion of PLA2-treated LDL particles
We have shown, that lipolysis of LDL with Type III sPLA2 induced aggregation of the particles in the presence, but not in the absence of albumin (Study II, Figs. 2A and 6A). 
The likely reason for the effect is sequestration of negatively charged FFAs by albumin (Study 
II, Fig. 4.). This could also explain why in some studies (Study II) [303;319] LDL was found to 
aggregate, while in others [1;87;122] this was not observed. In addition, aggregation of SMase-
treated LDL, but not of SMase-treated acLDL, shows that negatively charged LDL particles are 
resistant to aggregation [305]. We could also show that the enrichment of Type III sPLA
2
-treated 
heparin-bound LDL particles with FFAs detached 70% of the particles (Study II, Fig 5). Interest-
ingly, these released particles contained about twice the amount of FFAs as compared to heparin-
bound particles resembling the electronegative LDL of plasma [15]. The detached particles did 
not aggregate unless they were treated with albumin, whereas the heparin-bound particles, that 
also contained substantial amount of FFAs (Study II, Fig. 5B), were still able to aggregate (Study 
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II, Fig. 6C). Similarly, other negatively charged modified LDL preparations, such as oxdized 
LDL, electronegative LDL, naturally occurring multiply modified LDL, and E-LDL, are able to 
aggregate and/or fuse suggesting that other interactions can overcome, at least partially, the charge 
repulsion between particles. 
 
6. Cathepsin D and LAL can be found extracellularly  
    in human atherosclerotic lesions
Cathepsin D is a protease, which initiates degradation of LDL in lysosomes. It has been found intracellularly in the atherosclerotic lesions [115], and is secreted by cultured monocyte-
derived macrophages [213]. LAL, again, the major cholesteryl esterase in endo-lysosomal com-
partments, has been found in macrophage foam cells and deep in the intimal fibrous tissues [59], 
but there is little in vivo evidence of secretion of LAL. Thus, sections of human coronary arteries 
arteries obtained from autopsies or, to avoid post-mortem release of these enzymes, from heart 
transplantations were first immunohistochemically stained for cathepsin D and LAL. We found 
that the amounts of cathepsin D and LAL in the normal arterial intima were so low that they were 
barely detectable by immunohistochemistry (Study III, Fig. 1A and C). In contrast, in advanced 
atherosclerotic lesions the amounts of cathepsin D and LAL were dramatically increased (Study 
III, Fig. 1B and D). Both enzymes co-localized with infiltrations of macrophages (Study III, Fig. 
1F) and showed both punctate cellular and diffuse extracellular staining, whereas a lysosomal 
marker, the lysosome-associated membrane protein 1 showed only punctate intracellular staining 
(Study III, Fig. 1H), suggesting that cathepsin D and LAL were actively secreted from intimal 
macrophages.  Moreover, sections in which primary antibodies were replaced with non-spesific 
rabbit IgG or isotype-matched mouse IgG remained unstained. Consistent with these results, other 
lysosomal cathepsins, i.e. cathepsin F [322], cathepsins S and K [268], and cathepsin B [111] have 
also been found extracellularly in atherosclerotic lesions. Taken together, the present and previous 
findings suggest that a number of different lysosomal enzymes are present extracellularly in the 
human atherosclerotic intima.
7. Macrophage-derived cathepsin D and LAL induce  
    fusion of LDL particles in vitro
Various agents, such as immunocomplexes [35] and zymosan [62], can trigger the release of lysosomal enzymes from macrophages. Thus, we have modeled a inflammation-induced 
stimulation of secretion of lysosomal acid hydrolases by incubating human monocyte-derived 
macrophages with zymosan A opsonized with fresh human serum (Zop) [106]. The level of lac-
tate dehydrogenase activity in the control media (6.1 ± 3.5% of total cellular activity) and the 
conditioned media from Zop-treated macrophages (6.5± 0.3% of total cellular activity) was low, 
indicating that Zop did not exert cytotoxic effects on macrophages. Incubation of LDL with the 
conditioned medium from Zop-treated macrophages induced fusion of LDL particles as analyzed 
by electron microscopy (Study III, online supplement, Fig. 1).  The largest H-LDL particles were 
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about 200 nm in diameter, resembling those found extracellularly in atherosclerotic lesions. Fusion 
of the LDL particles appeared to be independent of oxidation, since the samples contained EDTA, 
the amount of thiobarbituric acid-reactive substances in H-LDL (< 1 nmol/mg LDL) was low as 
compared with oxLDL (22 nmol/mg LDL), and the modification was unaffected by the presence 
of 20 µM butylated hydroxytoluene, an inhibitor of peroxidation. In addition, incubation of LDL in 
the culture medium with or without Zop particles in the absence of macrophages failed to generate 
trichloroacetic acid-soluble radioactivity and conditioned medium from unstimulated macrophages 
did not increase turbidity of the LDL sample (Study III, Fig. 2C), showing that proteolytic activity 
was released from stimulated macrophages. Analysis of the lipid composition of the H-LDL particles 
revealed that the amounts of CEs and triglycerides were significantly decreased and the amounts 
of UC and FFAs were significantly increased in H-LDL as compared with native LDL (Study III, 
Fig. 4A). No significant hydrolysis of PC or SM was found suggesting that the macrophage-con-
ditioned media did not contain PLA
2
- or SMase-like activities. In addition, immunodepletion of 
LAL from the conditioned medium totally inhibited release of FFAs from LDL (Study III, Fig. 4B) 
suggesting that LAL was the predominant lipase degrading LDL in the macrophage-conditioned 
media. Finally, large amounts of LAL were found in the macrophage-conditioned media by Western 
blotting (Study III, Fig. 5B), suggesting that Zop-induced secretion of active form(s) of LAL into 
the culture media, indeed, induced degradation of the core lipids of LDL in vitro.
Characterization of proteolytic activity in the macrophage-conditioned media by protease inhibitors 
revealed that proteolytic degradation of LDL was accomplished by an aspartic protease (Study 
III, Fig. 3A). Mature form(s) of cathepsin D, an aspartic protease, were found by Western blot-
ting (Study III, Fig. 5A), suggesting that cathepsin D could have at least promoted proteolysis of 
LDL. This was confirmed by abolishing activity of cathepsin D in the medium. We found, that 
immunodepletion of the macrophage-conditioned media with antibody against cathepsin D totally 
blocked H-LDL proteolysis (Study III, Fig. 3B). Moreover, the pattern of apoB-100 fragmenta-
tion of H-LDL resembled the one that had been produced by incubating LDL with commercial 
cathepsin D, but was totally different from patterns obtained with thrombin, kallikrein, or pronase 
(Study III, Fig. 3C-D). However, we cannot exclude that the macrophage-conditioned medium 
contained a minor activity of other proteases as well. Similar proteolytic activity, albeit smaller in 
extent, was released from macrophages when they were incubated with LDL immunocomplexes, 
vortexed LDL, or zymosan particles. Thus, Zop-treated macrophages secrete active cathepsin D 
and LAL into the cell culture media. A combined action of these enzymes transform LDL into the 
fused particles, which resemble those found extracellularly in human atherosclerotic lesions.
8. H-LDL induces formation of foam cells
When mouse peritoneal macrophages and human coronary artery SMCs were incubated with 50 µg/ml of H-LDL and stained with Oil Red O, cytoplasmic lipid inclusions were found 
in both the macrophages (Study III, Fig. 6A-D) and in SMCs (Study III, Fig. 7), showing that 
H-LDL had transformed them into foam cells. Native LDL or oxLDL failed to induce formation 
of cytoplasmic lipid droplets in either cell type (Study III, Figs. 6 and 7). In addition, analysis of 
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human monocyte-derived macrophages by electron microscopy revealed that numerous cytoplasmic 
lipid inclusions had appeared after incubation with H-LDL (Study III, online supplement, Fig. 
2). Untreated and native LDL-treated macrophages that served as controls were totally devoid of 
intracellular lipid droplets. Determination of the cellular lipid content by high performance thin 
layer chromatography showed that H-LDL had increased the levels of both unesterified and esteri-
fied cholesterol in macrophages (Study III, Fig. 6E-F). In conclusion, H-LDL was avidly taken up 
by macrophages and SMCs and induced their transformation into foam cells.
The mechanisms of uptake of H-LDL by macrophages were studied in competition experiments 
(Study III). In the presence of 20-fold excess of unlabeled lipoproteins, the degradation of H-
LDL by macrophages was inhibited by 53% with LDL, by 59% with acLDL, by 69% with mildly 
oxidized (3 h) LDL, by 57% with totally (18 h) oxidized LDL, and by 67% with the unlabeled 
H-LDL. In addition, anti-CD36 and anti-LRP antibodies decreased the degradation of H-LDL in 
macrophages (Hakala et al. unpublished). In accord with our findings, uptake of E-LDL (resembling 
H-LDL) was previously shown to be partially mediated by CD36 [116] and aggregated LDL was 
taken up through LRP into macrophages [231]. Therefore, our preliminary results suggest that 
SRs, e.g. CD36, and a member(s) of LDL receptor family, e.g. LRP, may participate in the uptake 
of H-LDL by macrophages. 
9. H-LDL induces secretion of pro-inflammatory           
    cytokines by cultured vascular cells
It has been shown that loading of macrophages with lipid induces the expression of a variety of inflammatory mediators, such as cytokines [146;294] and, as described above, H-LDL is able 
to induce accumulation of lipid in macrophages and SMCs. Thus, the ability of H-LDL to induce 
secretion of pro-inflammatory cytokines was studied. First, the expression of common human 
cytokine genes in human monocyte-derived macrophages, human coronary artery SMCs, and hu-
man coronary artery ECs was screened with a complementary DNA array (GEArray). Untreated 
cells and lipopolysaccharide-treated cells served as controls for the experiment. Surprisingly, of 
the 96 cytokine genes in the array, only IL-8, IL-1β, and IL-6 were up-regulated when compared 
to untreated cells (Study IV). Notably, neither expression of TNF-α, the major pro-inflamma-
tory cytokine induced by lipopolysaccharide and oxLDL, nor expression of anti-inflammatory 
cytokines, e.g. transforming growth factor-β or IL-10, were found to be up-regulated by H-LDL 
treatment. Indeed, the level of endotoxin in all the H-LDL preparations was tested and found to 
be substantially lower than the highest amount of lipopolysaccharide that was not able to induce 
cellular effects. In addition, no generation of thiobarbituric acid reactive substances was found in 
the H-LDL preparations. Analysis of the secretion of the cytokines showed that H-LDL had induced 
secretion of IL-8 from macrophages and ECs and of IL-6 from macrophages and SMCs (Study 
IV, Fig. 1). Surprisingly, only a trace amount of IL-1β was secreted from the cells even after 24 
h of stimulation with H-LDL suggesting post-transcriptional degradation or cellular segregation 
of the cytokine. All the studied types of cells, however, secreted MCP-1, an important chemoat-
tractant for monocytes. Interestingly, H-LDL and E-LDL, representing similar types of modified 
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LDLs only partially overlap in their biological effects. Both H-LDL (Hakala et al. unpublished 
data) and E-LDL [19] bind CRP and activate complement, but they induce differential secretion 
of pro-inflammatory cytokines in the cultured vascular cells. They induce secretion of MCP-1 
from macrophages and SMCs, but only H-LDL is able to induce a massive secretion of IL-8 and 
IL-6 from macrophages and SMCs (Study IV). In addition, both H-LDL and E-LDL are able to 
induce secretion of IL-8 from ECs, but only H-LDL induce secretion of MCP-1 from ECs. Thus, 
we have shown that H-LDL is a potent novel inducer of secretion of pro-inflammatory cytokines 
from cultured vascular cells. However, the actual molecule(s) that initiate secretion of pro-inflam-
matory cytokines from the vascular cells remains to be studied, the probable candidates being 
FFAs and UC of H-LDL.
We next studied signaling pathway(s) in human monocyte-derived macrophages that were treated 
with H-LDL and analyzed for the secretion of IL-8 as a measure of the inflammatory response of 
the cells. Expression of IL-8 in H-LDL-treated macrophages was first confirmed by reverse-tran-
scriptase polymerase chain reaction, which showed that H-LDL induced about six-fold increase 
in the amount of IL-8 messenger RNA (Study IV, Fig. 2). The role of MAPKs in the inflammatory 
response of cells to H-LDL was studied by using MAPK specific inhibitors. Only p38 MAPK in-
hibitor, SB203580, was able to totally block the release of IL-8 from H-LDL treated macrophages 
(Study IV, Fig. 3A), whereas inhibition of ERK1/2 or JNK MAPKs had only a weak effect. This 
is in accordance with previous results showing that in the intimal cells, p38 plays a major role in 
inflammatory response [85]. Indeed, analysis of the phosphorylation of p38 MAPK in macrophages 
by Western blotting showed that H-LDL induced transient activation of the p38 MAPK between 
5-30 minutes of incubation (Study IV, Fig. 3B). Thus, activation of the p38 MAPK appears to play 
an important role in the expression of IL-8 by H-LDL-treated macrophages.   
Initiation of the gene transcription involves nuclear translocation of transcription factors. It has 
been shown that the promoter area of IL-8 contains binding sites for NF-κB and AP-1 transcription 
factors [180;222] and  that their nuclear translocation is needed for IL-8 secretion from human 
monocytes [109]. In addition, it has been suggested that NF-κB dimers promote gene transcription 
either alone or as part of a complex of several coactivators [247] and with other transcription fac-
tors, such as activator protein-1 (AP-1) [308]. Thus, activation of NF-κB and AP-1 transcription 
factors was analyzed in H-LDL-treated macrophages by the electrophoretic mobility shift assay. 
We found that H-LDL induced time-dependent nuclear translocation of both NF-κB and AP-1 in 
macrophages (Study IV, Fig. 4A and B). When inhibitors of NF-κB and AP-1 were included in 
the reaction mixtures, it was found that NF-κB was more important in the release of IL-8 (Study 
IV, Fig. 5). Inhibition of the secretion of IL-8 by caffeic acid phenylethyl ester and sulfasalazin, 
two antioxidants, as well as increased secretion by MG-132, an activator of the production of 
reactive oxygen species [304], suggest that secretion of IL-8 from H-LDL-treated macrophages 
may involve generation of reactive oxygen species beside activation of p38 MAPK and the NF-κB 
transcription factor. Thus, nuclear translocation of NF-κB was needed to secretion of IL-8 from 
H-LDL-treated macrophages.
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10. Proposed atherogenic properties of sPLA2 and  
      lysosomal acid hydrolases modified LDL.
We have shown that Type IIA sPLA2 (Study I) and lysosomal acid hydrolases, i.e. cathepsin D and LAL (Study III), induce fusion of LDL particles, which has been shown to increase 
their retention to proteoglycans in vitro [197;198;319;322] (Figure 10). The action of both Type 
IIA sPLA
2 
or lysosomal acid hydrolases on LDL produces FFAs, which can increase secretion of 
PGs from SMCs [193]. In addition, lipolysis of LDL with Type IIA sPLA
2 
generates LPC, another 
bioactive molecule, which participates in the chemotaxis of monocytes [214]. Moreover, both 
sPLA
2
-treated LDL [11;175] and H-LDL (Study III) are taken up avidly by vascular cells, which 
induces their transformation into foam cells and may increase their ability to secrete pro-inflam-
matory cytokines, such as IL-8, IL-6, and MCP-1 (Study IV). The pro-inflammatory cytokines 
can increase, again, the amount of monocytes (IL-8 and MCP-1) [76] and SMCs (IL-8) [318] in 
the intima, and may induce proliferation of SMCs (IL-6 and IL-8) [182;318]. In addition, IL-6 
drives differentiation of monocytes into macrophages [52]. Finally, the lipids liberated from dy-
ing foam cells and formed extracellularly in the intima may induce formation of a lipid-rich core 
in the intima.
Figure 10. Proposed model of atherogenic properties of LDL modifications induced by PLA2 or by lysosomal acid 
hydrolases.
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Lipolysis of LDL with Type IIA sPLA
2
 induced fusion of LDL particles in the presence 
of human aortic PGs (Study I). The binding strength of the fused LDL particles to human 
aortic PGs appeared be substantially increased, which led to increased retention of LDL in 
PG-matrix. Thus, Type IIA sPLA
2
 may induce formation and accumulation of LDL-derived 
lipid droplets in PG-rich areas of arterial intima during atherogenesis.    
Lipolysis of LDL with PLA
2
 induced particle aggregation in the absence and fusion in the 
presence of heparin-GAG (study II). Even a transient interaction of LDL with GAGs pro-
moted fusion of PLA
2
-treated LDL particles. Thus, the presence of GAGs was a prerequisite 
for fusion of the PLA
2
-treated LDL particles.
Only low amounts of cathepsin D and LAL, two lysosomal acid hydrolases, can be found in 
grossly normal intima, but their concentrations increased dramatically during atherogenesis 
(Study III). Notably, both enzymes were found extracellularly in the human atherosclerotic 
lesions where they mainly colocalized with infiltrations of macrophages suggesting secretion 
by macrophages. Stimulated monocyte-derived macrophages released substantial amounts 
of cathepsin D and LAL into the cell culture medium and they induced fusion of LDL par-
ticles (H-LDL) in vitro. Thus, our in vivo and in vitro results suggest that lysosomal acid 
hydrolases released from macrophages may induce formation of LDL-derived lipid droplets 
and vesicles in the human arterial intima.  
H-LDL was avidly taken up by human macrophages and SMCs in vitro (Study III). In ad-
dition, H-LDL also induced secretion of pro-inflammatory cytokines, i.e. IL-8, IL-6, and 
MCP-1, from human cultured vascular cells (Study IV). Thus, H-LDL may transform mac-
rophages and SMCs into foam cells and accelerate inflammatory reaction in arterial intima 
during atherogenesis. 
Thus, our in vitro data strongly suggest that PLA
2
 and lysosomal acid hydrolases, which 
have both been found in human atherosclerotic lesions, may induce atherogenic changes in 
LDL, and so participate in the development of atherosclerosis.
SUMMARY AND CONCLUSIONS
1.
2.
3.
4.
In this thesis, we have studied aggregation and fusion of enzymatically-modified LDL particles, i.e. LDL treated with sPLA
2
 and lysosomal acid hydrolases, and the atherogenic properties of 
such modified LDL. The answers for the specific aims of the study were:
52
REFERENCES
53
ACKNOWLEDGMENTS
ACKNOWLEDGEMENTS
This study was carried out in the Wihuri Research Institute during years 1996-2005. I am grate-ful to all the people involved in my studies. In particular, I want to express my           
  warmest gratitude to the following persons:
Professor Petri Kovanen, the head of the Wihuri Research Institute and my supervisor for 
his trust, guidance, and support during these years.
Docent Katariina Öörni, my “daily” supervisor for her great experties in the field of 
lipoproteins and proteoglycans. 
Doctor Markku Pentikäinen, my second “daily” supervisor for his never-ending knowl-
edge of everything.
Professor Terho Lehtimäki and Docent Pentti Somerharju, both for their expert review of 
this manuscript and for their constructive comments on the text.
Professor Eva Hurt-Camejo, Docent Mika Ala-Korpela, Docent Ken Lindstedt, Drs. Petri 
Laine, Hong Du and Gregory A. Grabowski, and MD Riina Oksjoki for co-authorship. 
M.Sc. Laura Nurmi and B.Sc. Anna Oksaharju for their help in the field of molecular 
biology. 
Päivi Hiironen, Laura Vatanen, Mari Jokinen and Leena ”Lennu” Saikko for their excel-
lent technical skills. 
Mrs. Jean Margaret Perttunen for revision of the English language of the thesis and the 
original publications.
All the members of the Wihuri staff for the nice time during coffee breaks and parties in 
the Wihuri library.
My parents, Hannu and Liisa, are warmly acknowledged for their encouragement and 
interest for my work during these years.
And last, but not least, I wish to express my warmest thanks to Terhi & The boys, my dear 
family, for their love, support, and flexibility. Without you, I would have been like  
a hiker in the mountain without food and companionship.
*
*
*
*
*
*
*
*
*
*
Aarne Koskelo Foundation and the Magnus Ehrnrooth Foundation will be acknowledged for the 
financial support for the thesis. 
Helsinki, October 2005
♥
52
REFERENCES
53
REFERENCES
1.  Aggerbeck LP, Kezdy FJ, and Scanu AM, Enzymatic probes of lipoprotein structure. Hydrolysis of human serum 
     low density lipoprotein-2 by phospholipase A2. J.Biol.Chem. 251: 3823-3830, 1976.
  
2.   Aiello RJ, Bourassa PA, Lindsey S, Weng W , Natoli E, Rollins BJ, and Milos PM, Monocyte chemoattractant 
 protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler.Thromb.Vasc.Biol. 19: 1518-
 1525, 1999.
 
3.  Alzoghaibi MA, Walsh SW, Willey A, Fowler AA, III, and Graham MF, Linoleic acid, but not oleic acid, upregulates 
the production of interleukin-8 by human intestinal smooth muscle cells isolated from patients with Crohn’s disease. 
Clin.Nutr. 22: 529-535, 2003.
 
4.  Amanuma K, Kanaseki T, Ikeuchi Y, Ohkuma S, and Takano T, Studies on fine structure and location of lipids in 
quick-freeze replicas of atherosclerotic aorta of WHHL rabbits. Virchows Arch A 410: 231-238, 1986.
 
5.  Andrews NC and Faller DV, A rapid micropreparation technique for extraction of DNA-binding proteins from limit-
ing numbers of mammalian cells. Nucleic Acids Res. 19:  2499, 1991.
 
6.  Anthonsen MW, Stengel D, Hourton D, Ninio E, and Johansen B, Mildly oxidized LDL induces expression of group 
IIa secretory phospholipase A
2
 in human monocyte-derived macrophages. Arterioscler.Thromb.Vasc.Biol. 20: 1276-
1282, 2000.
 
7.  Apostolopoulos J, Davenport P, and Tipping PG, Interleukin-8 production by macrophages from atheromatous 
plaques. Arterioscler.Thromb.Vasc.Biol. 16: 1007-1012, 1996.
 
8.  Asatryan L, Hamilton RT, Isas JM, Hwang J , Kayed R, and Sevanian A, LDL phospholipid hydrolysis produces 
modified electronegative particles with an unfolded apoB-100 protein. J.Lipid Res. 46: 115-122, 2005.
 
9.  Asmis R, Begley JG, Jelk J, and Everson WV, Lipoprotein aggregation protects human monocyte-derived macro-
phages from OxLDL-induced cytotoxicity. J.Lipid Res. 46: 1124-1132, 2005.
 
10.  Asmis R and Jelk J, Large variations in human foam cell formation in individuals: a fully autologous in vitro assay 
based on the quantitative analysis of cellular neutral lipids. Atherosclerosis 148: 243-253, 2000.
 
11.  Aviram M and Maor I, Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages. Biochem.Bi
ophys.Res.Commun. 185: 465-472, 1992.
 
12.  Avogaro P, Bon GB, and Cazzolato G, Presence of a modified low density lipoprotein in humans. Arterioscler. 8: 
79-87, 1988.
 
13.  Ball RY, Stowers EC, Burton JH, Cary NR, Skepper JN, and Mitchinson MJ, Evidence that the death of macrophage 
foam cells contributes to the lipid core of atheroma. Atherosclerosis 114: 45-54, 1995.
 
14.  Basu SK, Goldstein JL, Anderson RGW, and Brown MS, Degradation of cationized low density lipoprotein and regu-
lation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc.Natl.Acad.Sci.U.S.A. 
73: 3178-3182, 1976.
 
REFERENCES
54
REFERENCES
55
15.  Benitez S, Camacho M, Arcelus R, Vila L, Bancells C, Ordonez-Llanos J, and Sanchez-Quesada JL, Increased 
lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells 
Relationship with electronegative LDL. Atherosclerosis 177: 299-305, 2004.
 
16.  Benitez S, Sanchez-Quesada JL, Lucero L, Arcelus R, Ribas V, Jorba O, Castellvi A, Alonso E, Blanco-Vaca F, and 
Ordonez-Llanos J, Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are 
related to the increase in associated non-esterified fatty acids. Atherosclerosis 160: 223-232, 2002.
 
17.  Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, and Lose EJ, Biology of the syndecans: a family 
of transmembrane heparan sulfate proteoglycans. Annu.Rev.Cell Biol. 8: 365-393, 1992.
 
18.  Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum J, Walev I, and Wieland E, On the pathogenesis 
of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J.Exp.Med. 
182: 1959-1971, 1995.
 
19.  Bhakdi S, Torzewski M, Klouche M, and Hemmes M, Complement and atherogenesis: binding of CRP to degraded, 
nonoxidized LDL enhances complement activation. Arterioscler.Thromb.Vasc.Biol. 19: 2348-2354, 1999.
 
20. Bligh EG and Dyer WJ, A rapid method for total lipid extraction and purification. Can.J.Biochem.Physiol. 37: 911-
917, 1959.
 
21.  Boisvert WA, Santiago R, Curtiss LK, and Terkeltaub RA, A leukocyte homologue of the IL-8 receptor CXCR-2 
mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J.Clin.Invest  
101: 353-363, 1998.
 
22.  Bolton AE and Hunter WM, The labelling of proteins to high specific activities by conjugating to a 125I-containing 
acylating agent.  Biochem.J. 133: 529-539, 1973.
 
23.  Bondjers G, Wiklund O, Fager G, Camejo EH, and Camejo G, Transfer of lipoproteins from plasma to the cell 
populations of the normal and atherosclerotic arterial tissue. Eur.Heart J. 11 Suppl E:158-63.: 158-163, 1990.
 
24.  Boren J, Lee I, Zhu W, Arnold K, Taylor S, and Innerarity TL, Identification of the low density lipoprotein recep-
tor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial 
defective apo-B100. J.Clin.Invest 101: 1084-1093, 1998.
 
25.  Boring L, Gosling J, Cleary M, and Charo IF, Decreased lesion formation in CCR2-/- mice reveals a role for chem-
okines in the initiation of atherosclerosis. Nature 394: 894-897, 1998.
 
26.  Bretscher MS and Munro S, Cholesterol and the Golgi apparatus. Science 261: 1280-1281, 1993.
 
27.  Brown MS and Goldstein JL, A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47, 
1986.
 
28.  Camejo G, The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role 
in atherogenesis. Adv.Lipid Res. 19: 1-53, 1982.
 
29.  Camejo G, Fager G, Rosengren B, Hurt-Camejo E, and Bondjers G, Binding of low density lipoproteins by prote-
oglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J.Biol.Chem. 268: 14131-
14137, 1993.
 
REFERENCES
54
REFERENCES
55
30.  Camejo G, Hurt-Camejo E, Rosengren B, Wiklund O, Lopez F, and Bondjers G, Modification of copper-catalyzed 
oxidation of low density lipoprotein by proteoglycans and glycosaminoglycans. J.Lipid Res. 32: 1983-1991, 
1991.
 
31.  Camejo G, Hurt E, and Romano M, Properties of lipoprotein complexes isolated by affinity chromatography from 
human aorta. Biomed.Biochim.Acta 44: 389-401, 1985.
 
32.  Camejo G, Hurt E, Wiklund O, Rosengren B, Lopez F, and Bondjers G, Modifications of low-density lipoprotein 
induced by arterial proteoglycans and chondroitin-6-sulfate. Biochim.Biophys.Acta 1096: 253-261, 1991.
 
33.  Camejo G, Olofsson SO, Lopez F, Carlsson P, and Bondjers G, Identification of Apo B-100 segments mediating the 
interaction of low density lipoproteins with arterial proteoglycans. Arterioscler. 8: 368-377, 1988.
 
34.  Camejo G, Ponce E, Lopez F, Starosta R, Hurt E, and Romano M, Partial structure of the active moiety of a lipo-
protein complexing proteoglycan from human aorta. Atherosclerosis 49: 241-254, 1983.
 
35.  Cardella CJ, Davies P, and Allison AC, Immune complexes induce selective release of lysosomal hydrolases from 
macrophages. Nature 247: 46-48, 1974.
 
36.  Cardin AD and Weintraub HJR, Molecular modeling of protein-glycosaminoglycan interactions. Atherosclerosis 9: 
21-32, 1989.
 
37. Carr AC, Hypochlorous acid-modified low-density lipoprotein inactivates the lysosomal protease cathepsin B: protec-
tion by ascorbic and lipoic acids. Redox.Rep. 6: 343-349, 2001.
 
38.  Chait A and Wight TN, Interaction of native and modified low-density lipoproteins with extracellular matrix. 
Curr.Opin.Lipidol. 11: 457-463, 2000.
 
39.  Chang GJ, Woo P, Honda HM, Ignarro LJ, Young L, Berliner JA, and Demer LL, Oxidation of LDL to a biologically 
active form by derivatives of nitric oxide and nitrite in the absence of superoxide. Dependence on pH and oxygen. 
Arterioscler.Thromb. 14: 1808-1814, 1994.
 
40.  Chang MY, Potter-Perigo S, Wight TN, and Chait A, Oxidized LDL bind to nonproteoglycan components of smooth 
muscle extracellular matrices. J.Lipid Res.  42: 824-833, 2001.
 
41.  Chao FF, Amende LM, Blanchette-Mackie EJ, Skarlatos SI, Gamble W, Mergner WT, and Kruth HS, Unesteri-
fied cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas. Am.J.Pathol. 131: 73-83, 
1988.
 
42.  Chao FF, Blanchette-Mackie EJ, Chen YJ, Dickens BF, Berlin E, Amende LM, Skarlatos SI, Gamble W, Resau JH, 
Mergner WT, and Kruth HS, Characterization of two unique cholesterol-rich lipid particles isolated from human 
atherosclerotic lesions. Am.J.Pathol. 136: 169-179, 1990.
 
43. Chao FF, Blanchette-Mackie EJ, Tertov VV, Skarlatos SI, Chen YJ, and Kruth HS, Hydrolysis of cholesteryl ester 
in low density lipoprotein converts this lipoprotein to a liposome. J Biol.Chem. 267: 4992-4998, 1992.
 
44.  Chapman HA, Riese RJ, and Shi GP, Emerging roles for cysteine proteases in human biology. Annu.Rev.Physiol 
59:63-88.: 63-88, 1997.
 
45.  Chatterjee S, Neutral sphingomyelinase. Adv.Lipid Res. 25-48.: 25-48, 1993.
REFERENCES
56
REFERENCES
57
 
46.  Chatterton JE, Phillips ML, Curtiss LK, Milne R, Fruchart JC, and Schumaker VN, Immunoelectron microscopy of 
low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein 
surface. J.Lipid Res. 36: 2027-2037, 1995.
 
47.  Chen SH, Yang CY, Chen PF, Setzer D, Tanimura M, Li WH, Gotto AM, Jr., and Chan L, The complete cDNA and 
amino acid sequence of human apolipoprotein B-100. J.Biol.Chem. 261: 12918-12921, 1986.
 
48.  Chen W, Silver DL, Smith JD, and Tall AR , Scavenger receptor-BI inhibits ATP-binding cassette transporter 1- 
mediated cholesterol efflux in macrophages. J.Biol.Chem. 275: 30794-30800, 2000.
 
49.  Cherchi GM, Formato M, Demuro P, Masserini M, Varani I, and DeLuca G, Modifications of low density lipoprotein 
induced by the interaction with human plasma glycosaminoglycan-protein complexes. Biochim.Biophys.Acta 1212: 
345-352, 1994.
 
50.  Cheson BD and Morris SE, The role of complement and IgG on zymosan opsonization. Int.Arch.Allergy Appl.Immunol. 
66: 48-54, 1981.
 
51.  Chien MW, Chien CS, Hsiao LD, Lin CH, and Yang CM, OxLDL induces mitogen-activated protein kinase activa-
tion mediated via PI3-kinase/Akt in vascular smooth muscle cells. J.Lipid Res. 44: 1667-1675, 2003.
 
52.  Chomarat P, Banchereau J, Davoust J, and Palucka AK, IL-6 switches the differentiation of monocytes from dendritic 
cells to macrophages. Nat.Immunol. 1: 510-514, 2000.
 
53.  Cladaras C, Hadzopoulou-Cladaras M, Nolte RT, Atkinson D, and Zannis VI, The complete sequence and structural 
analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms. EMBO J. 5: 3495-
3507, 1986.
 
54.  Claise C, Edeas M, Chalas J, Cockx A, Abella A, Capel L, and Lindenbaum A, Oxidized low-density lipoprotein 
induces the production of interleukin-8 by endothelial cells. FEBS Lett. 398: 223-227, 1996.
 
55.  Crawford RS, Kirk EA, Rosenfeld ME, LeBoeuf RC, and Chait A, Dietary antioxidants inhibit development of fatty 
streak lesions in the LDL receptor-deficient mouse. Arterioscler.Thromb.Vasc.Biol. 18: 1506-1513, 1998.
 
56.  Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, and Fogelman 
AM, Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells 
and smooth muscle cells. Proc.Natl.Acad.Sci.U.S.A  87: 5134-5138, 1990.
 
57.  Daugherty A and Rateri DL, Presence of LDL receptor-related protein/alpha 2-macroglobulin receptors in macrophages 
of atherosclerotic lesions from cholesterol-fed New Zealand and heterozygous Watanabe heritable hyperlipidemic 
rabbits. Arterioscler.Thromb. 14: 2017-2024, 1994.
 
58.  Daugherty A, Zwiefel BS, Sobel BE, and Schonfeld G, Isolation of low density lipoprotein from atherosclerotic 
vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arterioscler. 8: 768-777, 1988.
 
59.  Davis HR, Glagov S, and Zarins CK, Role of acid lipase in cholesteryl ester accumulation during atherogenesis. 
Correlation of enzyme activity with acid lipase-containing macrophages in rabbit and human lesions. Atherosclerosis 
55: 205-215, 1985.
 
60.  Dawson TC, Kuziel WA, Osahar TA, and Maeda N, Absence of CC chemokine receptor-2 reduces atherosclerosis 
in apolipoprotein E-deficient mice. Atherosclerosis 143: 205-211, 1999.
REFERENCES
56
REFERENCES
57
 
61.  De Castellarnau C, Sanchez-Quesada JL, Benitez S, Rosa R, Caveda L, Vila L, and Ordonez-Llanos J, Electronega-
tive LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial 
cells. Arterioscler.Thromb.Vasc.Biol. 20: 2281-2287, 2000.
 
62.  Dean RT, Hylton W, and Allison AC, Lysosomal enzyme secretion by macrophages during intracellular storage of 
particles. Biochim.Biophys.Acta 584: 57-65, 1979.
 
63. Eckey R, Menschikowski M, Lattke P, and Jaross W, Minimal oxidation and storage of low density lipoproteins result in 
an increased susceptibility to phospholipid hydrolysis by phospholipase A2. Atherosclerosis 132: 165-176, 1997.
 
64.  Edwards IJ, Xu H, Obunike JC, Goldberg IJ, and Wagner WD, Differentiated macrophages synthesize a heparan 
sulfate proteoglycan and an oversulfated chondroitin sulfate proteoglycan that bind lipoprotein lipase. Arterioscler.T
hromb.Vasc.Biol. 15: 400-409, 1995.
 
65.  Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, and Protter AA, CD36 is a receptor for oxidized 
low density lipoprotein . J.Biol.Chem. 268: 11811-11816, 1993.
 
66.  Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, Kropf J, Kerber S, Breithardt G, Assmann G, and 
Cullen P, Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. 
Arterioscler.Thromb.Vasc.Biol. 19: 2355-2363, 1999.
 
67.  Feng B and Tabas I, ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. 
Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J.Biol.Chem. 277: 
43271-43280, 2002.
 
68.  Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX, Kuriakose G, Fisher EA, Marks 
AR, Ron D, and Tabas I,  The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. 
Nat.Cell Biol. 5: 781-792, 2003.
 
69.  Fielding CJ and Fielding PE, Cellular cholesterol efflux. Biochim.Biophys.Acta 1533: 175-189, 2001.
 
70.  Filip DA, Nistor A, Bulla A, Radu A, Lupu F, and Simionescu M, Cellular events in the development of valvular 
atherosclerotic lesions induced by experimental hypercholesterolemia. Atherosclerosis 67: 199-214, 1987.
 
71.  Flood C, Gustafsson M, Pitas RE, Arnaboldi L, Walzem RL, and Boren J, Molecular mechanism for changes in 
proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing 
human apolipoprotein B100. Arterioscler.Thromb.Vasc.Biol. 24: 564-570, 2004.
 
72.  Forte T and Nichols AV, Application of electron microscopy to the study of plasma lipoprotein structure. Adv.Lipid 
Res. 10: 1-41, 1972.
 
73.  Frank JS and Fogelman AM, Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by 
ultra-rapid freezing and freeze-etching. J.Lipid Res. 30: 967-978, 1989.
 
74.  Galis ZS, Alavi MZ, and Moore S, In situ ultrastructural characterization of chondroitin sulfate proteoglycans in 
normal rabbit aorta. J.Histochem.Cytochem. 40: 251-263, 1992.
 
75.  Gelb MH, Valentin E, Ghomashchi F, Lazdunski M, and Lambeau G, Cloning and recombinant expression of a 
structurally novel human secreted phospholipase A2. J.Biol.Chem. 275: 39823-39826, 2000.
 
REFERENCES
58
REFERENCES
59
76.  Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Jr., Luster AD, Luscinskas FW, 
and Rosenzweig A, MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow condi-
tions. Nature 398: 718-723, 1999.
 
77.  Gesquiere L, Cho W, and Subbaiah PV, Role of group IIa and group V secretory phospholipases A(2) in the metabo-
lism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. 
Biochemistry 41: 4911-4920, 2002.
 
78.  Gimpl G, Burger K, and Fahrenholz F, Cholesterol as modulator of receptor function. Biochemistry  36: 10959-
10974, 1997.
 
79.  Gorshkova IN, Menschikowski M, and Jaross W, Alterations in the physiochemical characteristics of low and high 
density lipoproteins after lipolysis with phospholipase A2. A spin-label study. Biochim.Biophys.Acta 1300: 103-113, 
1996.
 
80.  Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, and Charo IF, MCP-1 deficiency reduces 
susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J.Clin.Invest 103: 773-778, 
1999.
 
81.  Guyton JR and Klemp KF, Ultrastructural discrimination of lipid droplets and vesicles in atherosclerosis: value of 
osmium-thiocarbohydrazide-osmium and tannic acid-paraphenylenediamine techniques. J.Histochem.Cytochem. 36: 
1319-1328, 1988.
 
82.  Guyton JR and Klemp KF, Early extracellular and cellular lipid deposits in aorta of cholesterol-fed rabbits. Am.J.Pathol. 
141: 925-936, 1992.
 
83.  Guyton JR and Klemp KF, Development of the atherosclerotic core region. Chemical and ultrastructural analysis of 
microdissected atherosclerotic lesions from human aorta. Arterioscler.Thromb. 14: 1305-1314, 1994.
 
84.  Guyton JR, Klemp KF, Black BL, and Bocan TM, Extracellular lipid deposition in atherosclerosis . Eur.Heart J. 11 
Suppl E: 20-28, 1990.
 
85.  Hale KK, Trollinger D, Rihanek M, and Manthey CL, Differential expression and activation of p38 mitogen-activated 
protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J.Immunol. 162: 4246-4252, 1999.
 
86. Han SR, Momeni A, Strach K, Suriyaphol P, Fenske D, Paprotka K, Hashimoto SI, Torzewski M, Bhakdi S, and 
Husmann M, Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early 
atherogenesis. Arterioscler.Thromb.Vasc.Biol. 23: 661-667, 2003.
 
87.  Hanasaki K, Yamada K, Yamamoto S, Ishimoto Y, Saiga A, Ono T, Ikeda M, Notoya M, Kamitani S, and Arita H, 
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam 
cell formation. J.Biol.Chem. 277: 29116-29124, 2002.
 
88.  Havel RJ, Eder HA, and Bragdon JH, The distribution and chemical composition of ultracentrifugally separated 
lipoproteins in human serum. J.Clin.Invest. 34: 1345-1353, 1955.
 
89.  Hazell LJ, van den Berg JJ, and Stocker R, Oxidation of low-density lipoprotein by hypochlorite causes aggregation 
that is mediated by modification of lysine residues rather than lipid oxidation. Biochem.J. 302: 297-304, 1994.
 
REFERENCES
58
REFERENCES
59
90.  Hennig B, Toborek M, Joshi-Barve S, Barger SW, Barve S, Mattson MP, and McClain CJ, Linoleic acid activates 
nuclear transcription factor-kappa B (NF-kappa B) and induces NF-kappa B-dependent transcription in cultured 
endothelial cells. Am.J.Clin.Nutr. 63: 322-328, 1996.
 
91.  Hessler JR, Morel DW, Lewis LJ, and Chisolm GM, Lipoprotein oxidation and lipoprotein-induced cytotoxicity. 
Arterioscler. 3: 215-222, 1983.
 
92.  Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, and Ala-Korpela M, Structure of low density lipoprotein 
(LDL) particles: basis for understanding molecular changes in modified LDL. Biochim.Biophys.Acta 1488: 189-210, 
2000.
 
93.  Hiltunen TP and Ylä-Herttuala S, Expression of lipoprotein receptors in atherosclerotic lesions. Atherosclerosis 137: 
S81-S88, 1998.
 
94.  Hoff HF, Whitaker TE, and O’Neil J, Oxidation of low density lipoprotein leads to particle aggregation and altered 
macrophage recognition. J.Biol.Chem. 267: 602-609, 1992.
 
95.  Hollmann J, Schmidt A, von Bassewitz DB, and Buddecke E, Relationship of sulfated glycosaminoglycans and 
cholesterol content in normal and arteriosclerotic human aorta. Arterioscler. 9: 154-158, 1989.
 
96.  Holopainen JM, Medina OP, Metso AJ, and Kinnunen PK, Sphingomyelinase activity associated with human plasma 
low density lipoprotein. J.Biol.Chem. 275: 16484-16489, 2000.
 
97.  Holopainen JM, Metso AJ, Mattila JP, Jutila A, and Kinnunen PK, Evidence for the lack of a specific interaction 
between cholesterol and sphingomyelin. Biophys.J. 86: 1510-1520, 2004.
 
98.  Hoppe G, O’Neil J, and Hoff HF, Inactivation of lysosomal proteases by oxidized low density lipoprotein is partially 
responsible for its poor degradation by mouse peritoneal macrophages. J.Clin.Invest 94: 1506-1512, 1994.
 
99.  Hurt-Camejo E, Andersen S, Standal R, Rosengren B, Sartipy P, Stadberg, and Johansen B, Localization of non-
pancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on 
low-density lipoproteins. Arterioscler.Thromb.Vasc.Biol. 17: 300-309, 1997.
 
100. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Ahlstrom C, and Fager G, Effect of arterial proteoglycans and 
glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth 
muscle cells. Arterioscler.Thromb. 12: 569-583, 1992.
 
101. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Wiklund O, and Bondjers G, Differential uptake of proteoglycan-
selected subfractions of low density lipoprotein by human macrophages. J.Lipid Res. 31: 1387-1398, 1990.
 
102. Hurt-Camejo E, Umaerus M., Jönsson-Rylander A.-C., and Lundin S. Inlammation and hyperlipidemia differen-
tially regulate expression of secretory phospholipase A2 (sPLA2) Type IIA AND V in vivo. Atherosclerosis 6[1]. 
2005. Abstract
 
103. Hurt E, Bondjers G, and Camejo G, Interaction of LDL with human arterial proteoglycans stimulates its uptake by 
human monocyte-derived macrophages. J.Lipid Res. 31: 443-454, 1990.
 
104. Ikeda U, Ikeda M, Seino Y, Takahashi M, Kano S, and Shimada K, Interleukin 6 gene transcripts are expressed in 
atherosclerotic lesions of genetically hyperlipidemic rabbits. Atherosclerosis 92: 213-218, 1992.
 
105. Ikeda U, Ito T, and Shimada K, Interleukin-6 and acute coronary syndrome. Clin.Cardiol. 24: 701-704, 2001.
REFERENCES
60
REFERENCES
61
 
106. Imort M, Zuhlsdorf M, Feige U, Hasilik A, and von Figura K, Biosynthesis and transport of lysosomal enzymes 
in human monocytes and macrophages. Effects of ammonium chloride, zymosan and tunicamycin. Biochem.J 214: 
671-678, 1983.
 
107. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M,  Aoki T, Etoh T, Hashimoto T, Naruse M, Sano 
H, Utsumi H, and Nawata H, High glucose level and free fatty acid stimulate reactive oxygen species production 
through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes  49: 1939-
1945, 2000.
 
108. Iverius PH, The interaction between human plasma lipoproteins and connective tissue glycosaminoglycans. 
J.Biol.Chem. 247: 2607-2613, 1972.
 
109. Jefferson KK, Smith MF, Jr., and Bobak DA, Roles of intracellular calcium and NF-kappa B in the Clostridium 
difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J.Immunol. 163: 5183-5191, 
1999.
 
110. Jian B, Llera-Moya M, Ji Y, Wang N, Phillips MC, Swaney JB, Tall AR, and Rothblat GH, Scavenger receptor 
class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J.Biol.Chem. 
273: 5599-5606, 1998.
 
111. Jormsjö S, Wuttge DM, Sirsjo A, Whatling C, Hamsten A, Stemme S, and Eriksson P, Differential expression of 
cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. Am.J.Pathol. 
161: 939-945, 2002.
 
112. Järveläinen HT, Kinsella MG, Wight TN, and  Sandell LJ, Differential expression of small chondroitin/dermatan 
sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. 
J.Biol.Chem. 266: 23274-23281, 1991.
 
113. Kaartinen M, Penttilä A, and Kovanen PT, Accumulation of activated mast cells in the shoulder region of human 
coronary atheroma, the predilection site of atheromatous rupture. Circulation 90: 1669-1678, 1994.
 
114. Kaartinen M, Penttilä A, and Kovanen PT, Mast cells of two types differing in neutral protease composition in the 
human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty 
streaks, and the shoulder region of atheromas. Arterioscler.Thromb. 14: 966-972, 1994.
 
115. Kaesberg B, Harrach B, Dieplinger H, and Robenek H, In situ immunolocalization of lipoproteins in human arte-
riosclerotic tissue. Arterioscler.Thromb. 13: 133-146, 1993.
 
116. Kapinsky M, Torzewski M, Buchler C, Duong CQ, Rothe G, and Schmitz G, Enzymatically degraded LDL prefer-
entially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class 
B scavenger-receptor CD36. Arterioscler.Thromb.Vasc.Biol. 21: 1004-1010, 2001.
 
117. Kawabe Y, Cynshi O, Takashima Y, Suzuki T, Ohba Y, and Kodama T, Oxidation-induced aggregation of rabbit 
low-density lipoprotein by azo initiator. Arch.Biochem.Biophys. 310: 489-496, 1994.
 
118. Khalil MF, Wagner WD, and Goldberg IJ, Molecular interactions leading to lipoprotein retention and the initiation 
of atherosclerosis. Arterioscler.Thromb.Vasc.Biol. 24: 2211-2218, 2004.
 
119. Khoo JC, Miller E, McLoughlin P, and Steinberg D, Enhanced macrophage uptake of low density lipoprotein after 
self- aggregation. Arterioscler. 8: 348-358, 1988.
REFERENCES
60
REFERENCES
61
 
120. Kikugawa K, Beppu M, and Okamoto Y, Uptake by macrophages of low-density lipoprotein damaged by nitrogen 
dioxide in air . Lipids 30: 313-320, 1995.
 
121. Kishikawa H, Shimokama T, and Watanabe T, Localization of T lymphocytes and macrophages expressing IL-1, IL-2 
receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis. Virchows 
Arch.A Pathol.Anat.Histopathol. 423: 433-442, 1993.
 
122. Kleinman Y, Krul ES, Burnes M, Aronson W, Pfleger B, and Schonfeld G, Lipolysis of LDL with phospholipase 
A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J Lipid Res. 29: 729-
743, 1988.
 
123. Klouche M, Gottschling S, Gerl V, Hell W, Husmann M, Dorweiler B, Messner M, and Bhakdi S, Atherogenic 
properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. 
Arterioscler.Thromb.Vasc.Biol. 18: 1376-1385, 1998.
 
124. Klouche M, Rose-John S, Schmiedt W, and Bhakdi S, Enzymatically degraded, nonoxidized LDL induces human 
vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 101: 1799-1805, 
2000.
 
125. Knott TJ, Pease RJ, Powell LM, Wallis SC, Rall SC, Jr., Innerarity TL, Blackhart B, Taylor WH, Marcel Y, Milne 
R, and ., Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature 
323: 734-738, 1986.
 
126. Kokkonen JO and Kovanen PT, Proteolytic enzymes of mast cell granules degrade low density lipoproteins and 
promote their granule-mediated uptake by macrophages in vitro. J.Biol.Chem. 264: 10749-10755, 1989.
 
127. Kokkonen JO, Vartiainen M, and Kovanen PT, Low density lipoprotein degradation by secretory granules of rat 
mast cells. Sequential degradation of apolipoprotein B by granule chymase and carboxypeptidase A. J.Biol.Chem. 
261: 16067-16072, 1986.
 
128. Kolset SO and Gallagher JT, Proteoglycans in haemopoietic cells . Biochim.Biophys.Acta 1032: 191-211, 
1990.
 
129. Kovanen PT, The mast cell--a potential link between inflammation and cellular cholesterol deposition in atherogen-
esis. Eur.Heart J. 14 Suppl K: 105-117, 1993.
 
130. Kruth HS, Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, 
oil- red-O-negative particles. Am.J.Pathol. 114: 201-208, 1984.
 
131. Kruth HS, Huang W, Ishii I, and Zhang WY, Macrophage foam cell formation with native low density lipoprotein. 
J.Biol.Chem. 277: 34573-34580, 2002.
 
132. Kruth HS, Jones NL, Huang W, Zhao B, Ishii I, Chang J, Combs CA, Malide D, and Zhang WY, Macropinocy-
tosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. 
J.Biol.Chem. 280: 2352-2360, 2005.
 
133. Ku G, Thomas CE, Akeson AL, and Jackson RL, Induction of interleukin 1 beta expression from human periph-
eral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. J.Biol.Chem. 267: 14183-14188, 
1992.
REFERENCES
62
REFERENCES
63
 
134. Kudo I and Murakami M, Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 68-69: 3-58, 2002.
 
135. Kugiyama K, Ota Y, Sugiyama S, Kawano H , Doi H, Soejima H,  Miyamoto S, Ogawa H, Takazoe K, and Yasue 
H, Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. 
Am.J.Cardiol. 86: 718-722, 2000.
 
136. Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 
680-685, 1970.
 
137. Lamb DJ, Mitchinson MJ, and Leake DS, Transition metal ions within human atherosclerotic lesions can catalyse 
the oxidation of low density lipoprotein by macrophages. FEBS Lett. 374: 12-16, 1995.
 
138. Law SW, Grant SM, Higuchi K, Hospattankar A, Lackner K, Lee N, and Brewer HB, Jr., Human liver apoli-
poprotein B-100 cDNA: complete nucleic acid and derived amino acid sequence. Proc.Natl.Acad.Sci.U.S.A 83: 
8142-8146, 1986.
 
139. LeBaron RG, Zimmermann DR, and Ruoslahti E, Hyaluronate binding properties of versican. J.Biol.Chem. 267: 
10003-10010, 1992.
 
140. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, Hama S, Borromeo C, Evans RM, Berliner 
JA, and Nagy L, Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis 
of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ.Res. 87: 516-521, 2000.
 
141. Lee M, Lindstedt LK, and Kovanen PT, Mast cell-mediated inhibition of reverse cholesterol transport. 
Arterioscler.Thromb. 12: 1329-1335, 1992.
 
142. Lee RT, Yamamoto C, Feng Y, Potter-Perigo S, Briggs WH, Landschulz KT, Turi TG, Thompson JF, Libby P, and 
Wight TN, Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular 
smooth muscle cells. J.Biol.Chem. 276: 13847-13851, 2001.
 
143. Lehtimäki T, Lehtinen S, Solakivi T, Nikkilä M, Jaakkola O, Jokela H, Ylä-Herttuala S, Luoma JS, Koivula T, and 
Nikkari T, Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary 
artery disease. Arterioscler.Thromb.Vasc.Biol. 19: 23-27, 1999.
 
144. Lemaire S, Lizard G, Monier S, Miguet C , Gueldry S, Volot F, Gambert P, and Neel D, Different patterns of IL-
1beta secretion, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7alpha-, 
7beta-hydroxycholesterol, or 7-ketocholesterol. FEBS Lett. 440: 434-439, 1998.
 
145. Leventhal AR, Chen W, Tall AR, and Tabas I, Acid sphingomyelinase-deficient macrophages have defective cho-
lesterol trafficking and efflux. J.Biol.Chem. 276: 44976-44983, 2001.
 
146. Li Y, Schwabe RF, Devries-Seimon T, Yao PM, Gerbod-Giannone MC, Tall AR, Davis RJ, Flavell R, Brenner 
DA, and Tabas I, Free Cholesterol-loaded Macrophages Are an Abundant Source of Tumor Necrosis Factor-{alpha} 
and Interleukin-6: Model of NF-{kappa}B- and MAP kinase-dependent inflammation in advanced atherosclerosis. 
J.Biol.Chem. 280: 21763-21772, 2005.
 
147. Li Z, Yasuda Y, Li W, Bogyo M, Katz N, Gordon RE, Fields GB, and Bromme D, Regulation of collagenase 
activities of human cathepsins by glycosaminoglycans. J.Biol.Chem. 279: 5470-5479, 2004.
 
REFERENCES
62
REFERENCES
63
148. Liadaki KN, Liu T, Xu S, Ishida BY, Duchateaux PN, Krieger JP, Kane J, Krieger M, and Zannis VI, Binding of 
high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type 
I. Effect of lipid association and APOA-I mutations on receptor binding . J.Biol.Chem. 275: 21262-21271, 2000.
 
149. Lin SJ, Yen HT, Chen YH, Ku HH, Lin FY, and Chen YL, Expression of interleukin-1 beta and interleukin-1 receptor 
antagonist in oxLDL-treated human aortic smooth muscle cells and in the neointima of cholesterol-fed endothelia-
denuded rabbits. J.Cell Biochem. 88: 836-847, 2003.
 
150. Liscum L and Munn NJ, Intracellular cholesterol transport. Biochim.Biophys.Acta 1438: 19-37, 1999.
 
151. Liu-Wu Y, Hurt-Camejo E, and Wiklund O, Lysophosphatidylcholine induces the production of IL-1beta by human 
monocytes. Atherosclerosis 137: 351-357, 1998.
 
152. Liu H, Scraba DG, and Ryan RO, Prevention of phospholipase-C induced aggregation of low density lipoprotein 
by amphipathic apolipoproteins. FEBS Lett. 316: 27-33, 1993.
 
153. Llorente-Cortes V and Badimon L, LDL receptor-related protein and the vascular wall: implications for athero-
thrombosis. Arterioscler.Thromb.Vasc.Biol. 25: 497-504, 2005.
 
154. Llorente-Cortes V,  Martinez-Gonzalez J, and Badimon L, LDL receptor-related protein mediates uptake of aggregated 
LDL in human vascular smooth muscle cells. Arterioscler.Thromb.Vasc.Biol. 20: 1572-1579, 2000.
 
155. Llorente-Cortes V,  Otero-Vinas M, Hurt-Camejo E, Martinez-Gonzalez J, and Badimon L, Human coronary 
smooth muscle cells internalize versican-modified LDL through LDL receptor-related protein and LDL receptors. 
Arterioscler.Thromb.Vasc.Biol. 22: 387-393, 2002.
 
156. Llorente-Cortes V,  Otero-Vinas M, Sanchez S, Rodriguez C, and Badimon L, Low-density lipoprotein upregulates 
low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of 
sterol regulatory element binding protein-2-dependent mechanism. Circulation 106: 3104-3110, 2002.
 
157. Locher R, Brandes RP, Vetter W, and Barton M, Native LDL induces proliferation of human vascular smooth 
muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases. Hypertension 39: 645-
650, 2002.
 
158. Loidl A, Claus R, Ingolic E, Deigner HP , and Hermetter A, Role of ceramide in activation of stress-associated 
MAP kinases by minimally modified LDL in vascular smooth muscle cells. Biochim.Biophys.Acta 1690: 150-158, 
2004.
 
159. Lottin H, Motta C, and Simard G, Differential effects of glycero- and sphingo-phospholipolysis on human high-
density lipoprotein fluidity. Biochim.Biophys.Acta 1301: 127-132, 1996.
 
160. Lougheed M, Moore ED, Scriven DR, and Steinbrecher UP, Uptake of oxidized LDL by macrophages differs from 
that of acetyl LDL and leads to expansion of an acidic endolysosomal compartment. Arterioscler.Thromb.Vasc.Biol.  
19: 1881-1890, 1999.
 
161.Lowry OH, Rosebrough NJ, Fall AL, and Randall RJ, Protein measurement with the Folin phenol reagent. J.Biol.Chem. 
193: 265-275, 1951.
 
REFERENCES
64
REFERENCES
65
162. Lund-Katz S, Ibdah JA, Letizia JY, Thomas MT, and Phillips MC, A 13C NMR characterization of lysine residues 
in apolipoprotein B and their role in binding to the low density lipoprotein receptor. J.Biol.Chem. 263: 13831-
13838, 1988.
 
163. Luostarinen R, Boberg M, and Saldeen T, Fatty acid composition in total phospholipids of human coronary arteries 
in sudden cardiac death. Atherosclerosis 99: 187-193, 1993.
 
164. Lupu F, Heim D, Bachmann F, and Kruithof EK, Expression of LDL receptor-related protein/alpha 2-macroglobulin 
receptor in human normal and atherosclerotic arteries. Arterioscler.Thromb. 14: 1438-1444, 1994.
 
165. Macek J, Krajickova J, and Adam M, Rapid determination of disaccharides from chondroitin and dermatan sulphates 
by high-performance liquid chromatography. J.Chromatogr. 414: 156-160, 1987.
 
166. Maor I, Mandel H, and Aviram M, Macrophage uptake of oxidized LDL inhibits lysosomal sphingomyelinase, thus 
causing the accumulation of unesterified cholesterol-sphingomyelin-rich particles in the lysosomes. A possible role 
for 7-Ketocholesterol. Arterioscler.Thromb.Vasc.Biol. 15: 1378-1387, 1995.
 
167. Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, Williams KJ, and Tabas I, Human vascular endothelial 
cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and cera-
mide-mediated cell signaling. J.Biol.Chem. 273: 4081-4088, 1998.
 
168. Margalit H, Fischer N, and Ben Sasson SA, Comparative analysis of structurally defined heparin binding sequences 
reveals a distinct spatial distribution of basic residues. J.Biol.Chem. 268: 19228-19231, 1993.
 
169. Masuda J and Ross R, Atherogenesis during low level hypercholesterolemia in the nonhuman primate. I. Fatty streak 
formation. Arterioscler. 10: 164-177, 1990.
 
170. Mateu L, Avila EM, Camejo G, Leon V, and Liscano N, The structural stability of low-density lipoprotein. A kinetic 
X-ray scattering study of its interaction with arterial proteoglycans. Biochim.Biophys.Acta 795: 525-534, 1984.
 
171. Maxfield FR and Wustner D, Intracellular cholesterol transport. J.Clin.Invest 110: 891-898, 2002.
 
172. Maziere C, Auclair M, Djavaheri-Mergny M, Packer L, and Maziere JC, Oxidized low density lipoprotein induces ac-
tivation of the transcription factor NF kappa B in fibroblasts, endothelial and smooth muscle cells. Biochem.Mol.Biol.Int. 
39: 1201-1207, 1996.
 
173. Mendis S, Magnesium, zinc, and manganese in atherosclerosis of the aorta. Biol.Trace Elem.Res. 22: 251-256, 
1989.
 
174. Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, and Jaross W, Secretory group II 
phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 118: 173-181, 1995.
 
175. Menschikowski M, Lattke P, Bergmann S, and Jaross W, Exposure of macrophages to PLA2-modified lipoproteins 
leads to cellular lipid accumulations. Analytical Cellular Pathology 9: 113-121, 1995.
 
176. Milanino R, Moretti U, Concari E, Marrella M, and Velo GP, Copper and zinc status in adjuvant-arthritic rat: studies 
on blood, liver, kidneys, spleen and inflamed paws. Agents Actions 24: 365-376, 1988.
 
177. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, and Witztum JL, Toll-like receptor 4-dependent and 
-independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscl
er.Thromb.Vasc.Biol. 25: 1213-1219, 2005.
REFERENCES
64
REFERENCES
65
 
178. Mora R, Lupu F, and Simionescu N, Prelesional events in atherogenesis. Colocalization of apolipoprotein B, un-
esterified cholesterol and extracellular phospholipid liposomes in the aorta of hyperlipidemic rabbit. Atherosclerosis 
67: 143-154, 1987.
 
179. Moynault A, Luciani MF, and Chimini G, ABC1, the mammalian homologue of the engulfment gene ced-7, is 
required during phagocytosis of both necrotic and apoptotic cells. Biochem.Soc.Trans. 26: 629-635, 1998.
 
180. Mukaida N, Okamoto S, Ishikawa Y, and Matsushima K, Molecular mechanism of interleukin-8 gene expression. 
J.Leukoc.Biol. 56: 554-558, 1994.
 
181. Munoz C, Pascual-Salcedo D, Castellanos MC, Alfranca A, Aragones J, Vara A, Redondo MJ, and de Landazuri 
MO, Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage 
colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa 
B and AP-1 transcription factors activity. Blood 88: 3482-3490, 1996.
 
182. Nabata T, Morimoto S, Koh E, Shiraishi T, and Ogihara T, Interleukin-6 stimulates c-myc expression and prolifera-
tion of cultured vascular smooth muscle cells. Biochem.Int. 20: 445-453, 1990.
 
183. Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa T, Tamura R, Matsumoto K, Kameda-
Takemura K, Yamashita S, and Matsuzawa Y, CD36, a novel receptor for oxidized low-density lipoproteins, is 
highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler.Thromb.Vasc.Biol. 19: 
1333-1339, 1999.
 
184. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, 
and ., Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall 
cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. 
J.Clin.Invest 88: 2039-2046, 1991.
 
185. Nelken NA, Coughlin SR, Gordon D, and Wilcox JN, Monocyte chemoattractant protein-1 in human atheromatous 
plaques. J.Clin.Invest 88: 1121-1127, 1991.
 
186. Neuzil J, Upston JM, Witting PK, Scott KF, and Stocker R, Secretory phospholipase A2 and lipoprotein lipase 
enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins. Biochem-
istry 37: 9203-9210, 1998.
 
187. Newby AC, An overview of the vascular response to injury: a tribute to the late Russell Ross. Toxicol.Lett. 112-113: 
519-529, 2000.
 
188. Ni W, Egashira K, Kitamoto S, Kataoka C , Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida KI, and 
Takeshita A, New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein 
E-knockout mice. Circulation 103: 2096-2101, 2001.
 
189. Nievelstein-Post P, Mottino G, Fogelman AM, and Frank J, An ultrastructural study of lipoprotein accumulation 
in cardiac valves of the rabbit. Arterioscler.Thromb. 14: 1151-1161, 1994.
 
190. Nievelstein PFEM, Fogelman AM, Mottino G, and Frank JS, Lipid accumulation in rabbit aortic intima 2 hours 
after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue. 
Arterioscler.Thromb. 11: 1795-1805, 1991.
 
191. O’Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, and Chait A, Comparison of 
apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with 
apolipoproteins. Circulation 98: 519-527, 1998.
REFERENCES
66
REFERENCES
67
 
192. Okazaki T, Bielawska A, Domae N, Bell RM, and Hannun YA, Characteristics and partial purification of a novel 
cytosolic, magnesium-independent, neutral sphingomyelinase activated in the early signal transduction of 1 alpha,25-
dihydroxyvitamin D3-induced HL-60 cell differentiation. J.Biol.Chem. 269: 4070-4077, 1994.
 
193. Olsson U, Bondjers G, and Camejo G, Fatty acids modulate the composition of extracellular matrix in cultured 
human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes 48: 
616-622, 1999.
 
194. Olsson U, Camejo G, Hurt-Camejo E, Elfsber K, Wiklund O, and Bondjers G , Possible functional interactions of 
apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. Arterioscler.Throm
b.Vasc.Biol. 17: 149-155, 1997.
 
195. Ono K and Han J, The p38 signal transduction pathway: activation and function. Cell Signal. 12 : 1-13, 2000.
 
196. Oram JF, Lawn RM, Garvin MR, and Wade DP, ABCA1 is the cAMP-inducible apolipoprotein receptor that medi-
ates cholesterol secretion from macrophages. J.Biol.Chem. 275: 34508-34511, 2000.
 
197. Paananen K and Kovanen PT, Proteolysis and fusion of low density lipoprotein particles independently strengthen 
their binding to exocytosed mast cell granules. J.Biol.Chem. 269: 2023-2031, 1994.
 
198. Paananen K, Saarinen J, Annila A, and Kovanen PT, Proteolysis and fusion of low density lipoprotein particles 
strengthen their binding to human aortic proteoglycans. J.Biol.Chem. 270: 12257-12262, 1995.
 
199. Panasenko OM, Vol’nova TV, Azizova OA, and Vladimirov YA, Free radical modification of lipoproteins and 
cholesterol accumulation in cells upon atherosclerosis. Free Radic.Biol.Med. 10: 137-148, 1991.
 
200. Pasquinelli G, Preda P, Vici M, Gargiulo M, Stella A, D’Addato M, and Laschi R, Electron microscopy of lipid 
deposits in human atherosclerosis. Scanning Microsc. 3: 1151-1159, 1989.
 
201. Pentikäinen MO,  Lehtonen EMP, and Kovanen PT, Aggregation and fusion of modified low density lipoprotein. 
J.Lipid Res. 37: 2638-2649, 1996.
 
202. Pentikäinen MO,  Lehtonen EMP, Öörni K, Lusa S, Somerharju P, Jauhiainen M, and Kovanen PT, Human 
arterial proteoglycans increase the rate of proteolytic fusion of low density lipoprotein particles. J.Biol.Chem. 272: 
25283-25288, 1997.
 
203. Perregaux DG, Dean D, Cronan M, Connelly P, and Gabel CA, Inhibition of interleukin-1 beta production by 
SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Mol.Pharmacol. 48: 
433-442, 1995.
 
204. Phillips MC, Johnson WJ, and Rothblat GH, Mechanisms and consequences of cellular cholesterol exchange and 
transfer. Biochim.Biophys.Acta 906: 223-276, 1987.
 
205. Piha M, Lindstedt L, and Kovanen PT, Fusion of proteolyzed LDL in the fluid phase: a novel mechanism generating 
atherogenic lipoprotein particles. Biochemistry 34: 10120-10129, 1995.
 
206. Pillarisetti S, Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. 
Trends Cardiovasc.Med. 10: 60-65, 2000.
 
207. Pober JS and Cotran RS, Cytokines and endothelial cell biology. Physiol Rev. 70: 427-451, 1990.
REFERENCES
66
REFERENCES
67
 
208. Podrez EA, Schmitt D, Hoff HF, and Hazen SL, Myeloperoxidase-generated reactive nitrogen species convert LDL 
into an atherogenic form in vitro. J.Clin.Invest 103: 1547-1560, 1999.
 
209. Polacek D, Byrne RE, and Scanu AM, Modification of low density lipoproteins by polymorphonuclear cell elastase 
leads to enhanced uptake by human monocyte-derived macrophages via the low density lipoprotein receptor pathway. 
J.Lipid Res. 29: 797-808, 1988.
 
210. Pollard H, Scanu AM, and Taylor EW, On the geometrical arrangement of the protein subunits of human serum 
low-density lipoprotein: evidence for a dodecahedral model. Proc.Natl.Acad.Sci.U.S.A 64: 304-310, 1969.
 
211. Porela P, Pulkki K, Voipio-Pulkki LM, Pettersson K, Leppanen V, and Nevalainen TJ, Level of circulating phos-
pholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction. Basic Res.Cardiol. 95: 
413-417, 2000.
 
212. Prinz W, Cholesterol trafficking in the secretory and endocytic systems. Semin.Cell Dev.Biol. 13: 197-203, 
2002.
 
213. Punturieri A, Filippov S, Allen E, Caras I, Murray R, Reddy V, and Weiss SJ, Regulation of elastinolytic cysteine 
proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp.Med. 192: 789-799, 2000.
 
214. Quinn MT, Parthasarathy S, and Steinberg D, Lysophosphatidylcholine: a chemotactic factor for human monocytes 
and its potential role in atherogenesis. Proc.Natl.Acad.Sci.U.S.A  85: 2805-2809, 1988.
 
215. Radding CM and Steinberg D, Studies on the synthesis and secretion of serum lipoproteins by rat liver slices. 
J.Clin.Invest. 39: 1560-1569, 1960.
 
216. Radhakrishnamurthy B, Tracy RE, Dalferes ERJ, and Berenson GS, Proteoglycans in human coronary arteriosclerotic 
lesions. Exp.Mol.Pathol. 65: 1-8, 1998.
 
217. Ramstedt B and Slotte JP, Interaction of cholesterol with sphingomyelins and acyl-chain-matched phosphatidylcho-
lines: a comparative study of the effect of the chain length. Biophys.J. 76: 908-915, 1999.
 
218. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton, AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel 
RJ, and  Kane JP, Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption 
from human atherosclerotic plaque. Arterioscler.Thromb. 14: 1767-1774, 1994.
 
219. Reagan JW, Jr., Hubbert ML, and Shelness GS, Posttranslational regulation of acid sphingomyelinase in niemann-
pick type C1 fibroblasts and free cholesterol-enriched chinese hamster ovary cells. J.Biol.Chem. 275: 38104-38110, 
2000.
 
220. Reddy VY, Zhang QY, and Weiss SJ, Pericellular mobilization of the tissue-destructive cysteine proteinases, cathe-
psins B, L, and S, by human monocyte-derived macrophages. Proc.Natl.Acad.Sci.U.S.A. 92: 3849-3853, 1995.
 
221. Ridker PM, Rifai N, Stampfer MJ, and Hennekens CH, Plasma concentration of interleukin-6 and the risk of future 
myocardial infarction among apparently healthy men. Circulation 101: 1767-1772, 2000.
 
222. Roebuck KA, Regulation of interleukin-8 gene expression. J.Interferon Cytokine Res. 19: 429-438, 1999.
 
REFERENCES
68
REFERENCES
69
223. Roebuck KA, Carpenter LR, Lakshminarayanan V, Page SM, Moy JN, and Thomas LL, Stimulus-specific regula-
tion of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and 
NF-kappaB. J.Leukoc.Biol. 65: 291-298, 1999.
 
224. Romano M, Romano E, Bjorkerud S, and Hurt-Camejo E, Ultrastructural localization of secretory type II phos-
pholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler.Thromb.Vasc.Biol.  
18: 519-525, 1998.
 
225. Rong JX, Berman JW, Taubman MB, and Fisher EA, Lysophosphatidylcholine stimulates monocyte chemoattract-
ant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler.Thromb.Vasc.Biol. 22: 1617-1623, 
2002.
 
226. Ross R, The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
 
227. Ross R, Atherosclerosis--an inflammatory disease. N.Engl.J Med.  340: 115-126, 1999.
 
228. Rus HG, Vlaicu R, and Niculescu F, Interleukin-6 and interleukin-8 protein and gene expression in human arterial 
atherosclerotic wall. Atherosclerosis 127: 263-271, 1996.
 
229. Ryoo SW, Kim DU, Won M, Chung KS, Jang YJ, Oh GT, Park SK, Maeng PJ, Yoo HS, and Hoe KL, Native LDL 
induces interleukin-8 expression via H2O2, p38 Kinase, and activator protein-1 in human aortic smooth muscle cells. 
Cardiovasc.Res. 62: 185-193, 2004.
 
230. Saadeddin SM, Habbab MA, and Ferns GA, Markers of inflammation and coronary artery disease. Med.Sci.Monit. 
8: RA5-12, 2002.
 
231. Sakr SW, Eddy RJ, Barth H, Wang F, Greenberg S, Maxfield FR, and Tabas I, The uptake and degradation of 
matrix-bound lipoproteins by macrophages require an intact actin Cytoskeleton, Rho family GTPases, and myosin 
ATPase activity. J.Biol.Chem. 276: 37649-37658, 2001.
 
232. Sanchez-Quesada JL, Camacho M, Anton R, Benitez S, Vila L, and Ordonez-Llanos J, Electronegative LDL of FH 
subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 
166: 261-270, 2003.
 
233. Saren P, Welgus HG, and Kovanen PT, TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase 
by human macrophages. J.Immunol. 157: 4159-4165, 1996.
 
234. Sartipy P, Bondjers G, and Hurt-Camejo E, Phospholipase A(2) type-II binds to extracellular matrix biglycan - 
Modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes. Arterioscler.Thromb.Vasc.Biol. 
18: 1934-1941, 1998.
 
235. Sartipy P, Camejo G, Svensson L, and Hurt-Camejo E, Phospholipase A(2) modification of low density lipoproteins 
forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J.Biol.Chem. 
274: 25913-25920, 1999.
 
236. Sartipy P, Johansen B, Camejo G, Rosengren B, Bondjers G, and Hurt-Camejo E, Binding of human phospholi-
pase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity. J.Biol.Chem. 271: 
26307-26314, 1996.
 
237. Sartipy P, Johansen B, Gasvik K, and Hurt-Camejo E, Molecular basis for the association of group IIA phospholipase 
A(2) and decorin in human atherosclerotic lesions. Circ.Res. 86: 707-714, 2000.
REFERENCES
68
REFERENCES
69
 
238. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, 
and Drexler H, Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential 
implications for inflammation and plaque instability. Circulation 101: 1372-1378, 2000.
 
239. Schissel SL, Jiang X, Tweedie-Hardman J, Jeong T, Camejo EH, Najib J, Rapp JH, Williams KJ, and Tabas I, 
Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at 
neutral pH. Implications for atherosclerotic lesion development. J.Biol.Chem. 273: 2738-2746, 1998.
 
240. Schissel SL, Schuchman EH, Williams KJ, and Tabas I, Zn2+-stimulated sphingomyelinase is secreted by many 
cell types and is a product of the acid sphingomyelinase gene. J.Biol.Chem. 271: 18431-18436, 1996.
 
241. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, and Tabas I, Rabbit aorta and human athero-
sclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall 
sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J.Clin.Invest. 98: 1455-
1464, 1996.
 
242. Schönherr E, Järveläinen HT, Kinsella MG, Sandell LJ, and Wight TN, Platelet-derived growth factor and trans-
forming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth 
muscle cells. Arterioscler.Thromb. 13: 1026-1036, 1993.
 
243. Segrest JP, Jones MK, Mishra VK, Anantharamaiah GM, and Garber DW, apoB-100 has a pentapartite structure 
composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detec-
tion by the computer program LOCATE. Arterioscler.Thromb. 14: 1674-1685, 1994.
 
244. Segrest JP, Jones MK, Mishra VK, Pierotti V, Young SH, Boren J, Innerarity TL, and Dashti N, Apolipoprotein 
B-100: conservation of lipid-associating amphipathic secondary structural motifs in nine species of vertebrates. J.Lipid 
Res. 39: 85-102, 1998.
 
245. Seifert PS, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, and Bhakdi S , Isolation and characterization of a 
complement-activating lipid extracted from human atherosclerotic lesions. J.Exp.Med. 172: 547-557, 1990.
 
246. Sevanian A, Wratten ML, McLeod LL, and Kim E, Lipid peroxidation and phospholipase A2 activity in liposomes 
composed of unsaturated phospholipids: a structural basis for enzyme activation. Biochim.Biophys.Acta 961: 316-
327, 1988.
 
247. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK, 
and Collins T, Transcriptional activation by NF-kappaB requires multiple coactivators . Mol.Cell Biol. 19: 6367-
6378, 1999.
 
248. Simionescu N, Vasile E, Lupu F, Popescu G, and Simionescu M, Prelesional events in atherogenesis. Accumula-
tion of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. 
Am.J.Pathol. 123: 109-125, 1986.
 
249. Singh RJ, Feix JB, Mchaourab HS, Hogg N , and Kalyanaraman B, Spin-labeling study of the oxidative damage 
to low-density lipoprotein. Arch.Biochem.Biophys. 320: 155-161, 1995.
 
250. Six DA and Dennis EA, The expanding superfamily of phospholipase A(2) enzymes: classification and characteriza-
tion. Biochim.Biophys.Acta 1488: 1-19, 2000.
 
251.Skiba PJ, Zha X, Maxfield FR, Schissel SL, and Tabas I, The distal pathway of lipoprotein-induced cholesterol 
esterification, but not sphingomyelinase-induced cholesterol esterification, is energy-dependent. J.Biol.Chem. 271: 
13392-13400, 1996.
REFERENCES
70
REFERENCES
71
 
252. Skålen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, and Boren J, Subendothelial reten-
tion of atherogenic lipoproteins in early atherosclerosis. Nature 417: 750-754, 2002.
 
253. Smith EB, The relationship between plasma and tissue lipids in human atherosclerosis. Adv.Lipid Res. 12: 1-49, 
1974.
 
254. Sonoki K, Yoshinari M, Iwase M, Iino K, Ichikawa K, Ohdo S, Higuchi S, and Iida M, Glycoxidized low-density 
lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial 
cells: relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism 51: 1135-1142, 
2002.
 
255. Sparrow CP, Parthasarathy S, and Steinberg D, Enzymatic modification of low density lipoprotein by purified lipoxy-
genase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res. 29: 745-753, 1988.
 
256. Spence MW, Sphingomyelinases. Adv.Lipid Res. 26:3-23.: 3-23, 1993.
 
257. Spence MW, Byers DM, Palmer FB, and Cook HW, A new Zn2+-stimulated sphingomyelinase in fetal bovine 
serum. J.Biol.Chem. 264: 5358-5363, 1989.
 
258. Stafforini DM, McIntyre TM, Zimmerman GA, and Prescott SM, Platelet-activating factor acetylhydrolases. 
J.Biol.Chem. 272: 17895-17898, 1997.
 
259. Staiger H, Staiger K, Stefan N, Wahl HG , Machicao F, Kellerer M, and Haring HU, Palmitate-induced interleukin-6 
expression in human coronary artery endothelial cells. Diabetes 53: 3209-3216, 2004.
 
260. Stary HC, Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler.Thromb
.Vasc.Biol. 20: 1177-1178, 2000.
 
261. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull WJ, Rosenfeld ME, Schwartz CJ, Wagner 
WD, and Wissler RW,  A definition of advanced types of atherosclerotic lesions and a histological classification of 
atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart 
Association. Circulation 92: 1355-1374, 1995.
 
262. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull WJ, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, 
and Wissler RW, A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the 
Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler.Thromb. 
14: 840-856, 1994.
 
263. Steinberg D, Low density lipoprotein oxidation and its pathobiological significance. J.Biol.Chem. 272: 20963-
20966, 1997.
 
264. Steinberg D, At last, direct evidence that lipoxygenases play a role in atherogenesis. J.Clin.Invest 103: 1487-1488, 
1999.
 
265. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, and Witztum JL, Beyond cholesterol. Modifications of low-
density lipoprotein that increase its atherogenicity. N.Engl.J.Med. 320: 915-924, 1989.
 
266. Subbanagounder G, Wong JW, Lee H, Faull KF, Miller E, Witztum JL, and Berliner JA, Epoxyisoprostane and 
epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation 
of these oxidized phospholipids in response to interleukin-1beta. J.Biol.Chem. 277: 7271-7281, 2002.
 
REFERENCES
70
REFERENCES
71
267. Suits AG, Chait A, Aviram M, and Heinecke JW, Phagocytosis of aggregated lipoprotein by macrophages: low 
density lipoprotein receptor-dependent foam-cell formation. Proc.Natl.Acad.Sci.U.S.A. 86: 2713-2717, 1989.
 
268. Sukhova GK, Shi GP, Simon DI, Chapman HA, and Libby P, Expression of the elastolytic cathepsins S and K in 
human atheroma and regulation of their production in smooth muscle cells. J Clin.Invest. 102: 576-583, 1998.
 
269. Sukovich DA, Kauser K, Shirley FD, DelVecchio V, Halks-Miller M, and Rubanyi GM, Expression of interleukin-6 
in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. Arterioscler.Thromb.Vasc.Biol. 
18: 1498-1505, 1998.
 
270. Suriyaphol P, Fenske D, Zahringer U, Han SR, Bhakdi S, and Husmann M, Enzymatically modified nonoxidized 
low-density lipoprotein induces interleukin-8 in human endothelial cells: role of free fatty acids. Circulation 106: 
2581-2587, 2002.
 
271. Tailleux A, Torpier G, Caron B, Fruchart JC, and Fievet C, Immunological properties of apoB-containing lipoprotein 
particles in human atherosclerotic arteries. J.Lipid Res. 34: 719-728, 1993.
 
272. Takabe W, Kanai Y, Chairoungdua A, Shibata N, Toi S, Kobayashi M, Kodama T, and Noguchi N, Lysophosphati-
dylcholine enhances cytokine production of endothelial cells via induction of L-type amino acid transporter 1 and cell 
surface antigen 4F2. Arterioscler.Thromb.Vasc.Biol. 24: 1640-1645, 2004.
 
273. Takahara N, Kashiwagi A, Maegawa H, and Shigeta Y, Lysophosphatidylcholine stimulates the expression and 
production of MCP-1 by human vascular endothelial cells. Metabolism 45: 559-564, 1996.
 
274. Takeya M, Yoshimura T, Leonard EJ, and Takahashi K, Detection of monocyte chemoattractant protein-1 in hu-
man atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum.Pathol. 24: 
534-539, 1993.
 
275. Tamminen M, Mottino G, Qiao JH, Breslow JL, and Frank JS, Ultrastructure of early lipid accumulation in ApoE-
deficient mice. Arterioscler.Thromb.Vasc.Biol. 19: 847-853, 1999.
 
276. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, and Curtiss LK, Oxidized LDL induces monocytic cell 
expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler.Thromb. 14: 47-53, 
1994.
 
277. Tertov VV, Bittolo-Bon G, Sobenin IA, Cazzolato G, Orekhov AN, and Avogaro P, Naturally occurring modified 
low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. 
Exp.Mol.Pathol. 62: 166-172, 1995.
 
278. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Jaakkola O, Solakivi T, Smirnov VN, and Orekhov AN, Multi-
ple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation 
and characterization. Lab.Invest. 67: 665-675, 1992.
 
279. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Orekhov, and AN, Lipoprotein aggregation as an essential condi-
tion of intracellular lipid accumulation caused by modified low density lipoproteins.  Biochem.Biophys.Res.Commun. 
163: 489-494, 1989.
 
280. Tertov VV, Sobenin IA, and Orekhov AN, Similarity between naturally occurring modified desialylated, electron-
egative and aortic low density lipoprotein. Free Radic.Res. 25: 313-319, 1996.
 
REFERENCES
72
REFERENCES
73
281. Tew DG, Southan C, Rice SQ, Lawrence MP , Li H, Boyd HF, Moores K, Gloger IS, and MacPhee CH, Purifica-
tion, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the 
oxidative modification of low-density lipoproteins. Arteriosclerosis, Thrombosis & Vascular Biology 16: 591-599, 
1996.
 
282. Tirziu D, Dobrian A, Tasca C, Simionescu M, and Simionescu N, Intimal thickenings of human aorta contain modi-
fied reassembled lipoproteins. Atherosclerosis 112: 101-114, 1995.
 
283. Tirziu D, Jinga VV, Serban G, and Simionescu M, The effect of low density lipoproteins modified by incubation 
with chondroitin 6-sulfate on human aortic smooth muscle cells.  Atherosclerosis 147: 155-166, 1999.
 
284. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B , Hooper S, Le Trong H, Cousens LS, 
Zimmerman GA, and ., Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374: 
549-553, 1995.
 
285. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, and Bhakdi S, Immunohis-
tochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement 
complex in the early atherosclerotic lesion. Arterioscler.Thromb.Vasc.Biol. 18: 369-378, 1998.
 
286. Torzewski M, Suriyaphol P, Paprotka K, Spath L, Ochsenhirt V, Schmitt A, Han SR, Husmann M, Gerl VB, Bhakdi 
S, and  Lackner KJ, Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin 
and matrix metalloproteinases in atherogenesis. Arterioscler.Thromb.Vasc.Biol. 24: 2130-2136, 2004.
 
287. Underwood KW, Jacobs NL, Howley A, and Liscum L, Evidence for a cholesterol transport pathway from lysosomes 
to endoplasmic reticulum that is independent of the plasma membrane. J.Biol.Chem. 273: 4266-4274, 1998.
 
288. van den Berg JJ, Op den Kamp JA, Lubin BH, and Kuypers FA, Conformational changes in oxidized phospholipids 
and their preferential hydrolysis by phospholipase A2: a monolayer study. Biochemistry 32: 4962-4967, 1993.
 
289. van Meer G, Transport and sorting of membrane lipids. Curr.Opin.Cell Biol. 5: 661-673, 1993.
 
290. Wang J, Liu H, Sykes BD, and Ryan RO , Identification and localization of two distinct microenvironments for the 
diacylglycerol component of lipophorin particles by 13C NMR. Biochemistry 34: 6755-6761, 1995.
 
291. Wang N, Lan D, Chen W, Matsuura F, and Tall AR, ATP-binding cassette transporters G1 and G4 mediate cellular 
cholesterol efflux to high-density lipoproteins. Proc.Natl.Acad.Sci.U.S.A 101: 9774-9779, 2004.
 
292. Wang N, Silver DL, Costet P, and Tall AR, Specific binding of ApoA-I, enhanced cholesterol efflux, and altered 
plasma membrane morphology in cells expressing ABC1. J.Biol.Chem. 275: 33053-33058, 2000.
 
293. Wang N, Silver DL, Thiele C, and Tall AR, ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol 
efflux regulatory protein. J.Biol.Chem. 276: 23742-23747, 2001.
 
294. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, and Tall A, Interleukin 8 is induced by cholesterol loading of 
macrophages and expressed by macrophage foam cells in human atheroma. J.Biol.Chem. 271: 8837-8842, 1996.
 
295. Weisgraber KH and Rall SC, Jr., Human apolipoprotein B-100 heparin-binding sites. J.Biol.Chem. 262: 11097-
11103, 1987.
 
296. Wight TN, Cell biology of arterial proteoglycans. Arterioscler.  9: 1-20, 1989.
 
REFERENCES
72
REFERENCES
73
297. Wight TN, The extracellular matrix and atherosclerosis. Curr.Opin.Lipidol. 6: 326-334, 1995.
 
298. Williams KJ, Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein 
retention and atherogenesis. Curr.Opin.Lipidol. 12: 477-487, 2001.
 
299. Williams KJ and Tabas I, The response-to-retention hypothesis of early atherogenesis. Arterioscler.Thromb.Vasc.Biol. 
15: 551-561, 1995.
 
300. Williams KJ and Tabas I, The response-to-retention hypothesis of atherogenesis reinforced. Curr.Opin.Lipidol. 9: 
471-474, 1998.
 
301. Witting PK, Pettersson K, Ostlund-Lindqvist AM, Westerlund C, Eriksson AW, and Stocker R, Inhibition by a 
coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein 
receptor gene double knockout mice. FASEB J. 13: 667-675, 1999.
 
302. Woenckhaus C, Kaufmann A, Bussfeld D, Gemsa D, Sprenger H, and Grone HJ, Hypochlorite-modified LDL: chemo-
tactic potential and chemokine induction in human monocytes. Clin.Immunol.Immunopathol. 86: 27-33, 1998.
 
303. Wooton-Kee CR, Boyanovsky BB, Nasser MS, de Villiers WJ, and Webb NR, Group V sPLA2 hydrolysis of 
low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. 
Arterioscler.Thromb.Vasc.Biol. 24: 762-767, 2004.
 
304. Wu HM, Chi KH, and Lin WW, Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen 
species production. FEBS Lett. 526: 101-105, 2002.
 
305. Xu XX and Tabas I, Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl 
ester accumulation in macrophages . J.Biol.Chem. 266: 24849-24858, 1991.
 
306. Yang CY, Chen SH, Gianturco SH, Bradley WA, Sparrow JT, Tanimura M, Li WH, Sparrow DA, DeLoof H, and 
Rosseneu M, Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. 
Nature 323 : 738-742, 1986.
 
307. Yasuda Y, Li Z, Greenbaum D, Bogyo M, Weber E, and Bromme D, Cathepsin V, a novel and potent elastolytic 
activity expressed in activated macrophages. J.Biol.Chem. 279: 36761-36770, 2004.
 
308. Yasumoto K, Okamoto S, Mukaida N, Murakami S, Mai M, and Matsushima K, Tumor necrosis factor alpha and 
interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting con-
currently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. J.Biol.Chem. 267: 22506-22511, 1992.
 
309. Yeagle PL, Modulation of membrane function by cholesterol. Biochimie 73: 1303-1310, 1991.
 
310. Yeh M, Leitinger N, de Martin R, Onai N , Matsushima K, Vora DK, Berliner JA, and Reddy ST,  Increased 
transcription of IL-8 in endothelial cells is differentially regulated by TNF-alpha and oxidized phospholipids. 
Arterioscler.Thromb.Vasc.Biol. 21: 1585-1591, 2001.
 
311. Ylä-Herttuala S, Is oxidized low-density lipoprotein present in vivo? Curr.Opin.Lipidol. 9: 337-344, 1998.
 
312. Ylä-Herttuala S, Jaakkola O, Ehnholm C, Tikkanen MJ, Solakivi T, Särkioja T, and Nikkari T, Characterization 
of two lipoproteins containing apolipoproteins B and E from lesion-free human aortic intima. J.Lipid Res. 29: 563-
572, 1988.
REFERENCES
74
 
313. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL, and Steinberg 
D, Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic 
lesions. Proc.Natl.Acad.Sci.U.S.A 88: 5252-5256, 1991.
 
314. Ylä-Herttuala S and Nikkari T, Effect of post-mortem time on the biochemical composition of coronary arteries. 
Atherosclerosis 56: 1-10, 1985.
 
315. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, and Witztum JL, Evidence for 
the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J.Clin.Invest. 
84: 1086-1095, 1989.
 
316. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Särkioja T, Witztum JL, and Steinberg D, Gene expres-
sion in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor 
messenger RNA colocalize with oxidation specific lipid-protein adducts. J.Clin.Invest 87: 1146-1152, 1991.
 
317. Young VM, Toborek M, Yang F, McClain CJ , and Hennig B, Effect of linoleic acid on endothelial cell inflamma-
tory mediators. Metabolism 47: 566-572, 1998.
 
318. Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL, and  Feuerstein GZ, Interleukin-8. A mitogen and 
chemoattractant for vascular smooth muscle cells. Circ.Res. 75: 1-7, 1994.
 
319. Öörni K, Hakala JK, Annila A, Ala-Korpela M, and Kovanen PT, Sphingomyelinase induces aggregation and fusion, 
but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading 
to increased binding strength of LDL to human aortic proteoglycans.  J.Biol.Chem. 273: 29127-29134, 1998.
 
320. Öörni K, Pentikäinen MO, Ala-Korpela M, and Kovanen PT, Aggregation, fusion, and vesicle formation of modi-
fied low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J.Lipid Res. 41: 
1703-1714, 2000.
 
321. Öörni K, Pentikäinen MO, Annila A, and Kovanen PT, Oxidation of low density lipoprotein particles decreases 
their ability to bind to human aortic proteoglycans: dependence on oxidative modification of the lysine residues. 
J.Biol.Chem. 272: 21303-21311, 1997.
322. Öörni K, Sneck M, Bromme D, Pentikainen MO, Lindstedt KA, Mäyränpää M, Aitio H, and Kovanen PT, Cysteine 
protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured  
macrophages, and modifies low density lipoprotein particles in vitro. J.Biol.Chem. 279: 34776-34784, 2004.
